The Dynamic Roles of Red Blood Cell in Microcirculation by Zhou, Sitong
Rochester Institute of Technology 
RIT Scholar Works 
Theses 
7-15-2019 
The Dynamic Roles of Red Blood Cell in Microcirculation 
Sitong Zhou 
sz4796@rit.edu 
Follow this and additional works at: https://scholarworks.rit.edu/theses 
Recommended Citation 
Zhou, Sitong, "The Dynamic Roles of Red Blood Cell in Microcirculation" (2019). Thesis. Rochester 
Institute of Technology. Accessed from 
This Dissertation is brought to you for free and open access by RIT Scholar Works. It has been accepted for 
inclusion in Theses by an authorized administrator of RIT Scholar Works. For more information, please contact 
ritscholarworks@rit.edu. 
1 
 
R.I.T 
 
The Dynamic Roles of Red Blood Cell in 
Microcirculation 
by 
Sitong Zhou 
A dissertation submitted in partial fulfillment of the requirements  
for the degree of Doctorate of Philosophy in Microsystems Engineering 
 
 
Microsystems Engineering Program 
Kate Gleason College of Engineering 
 
 
 
 
 
 
Rochester Institute of Technology 
Rochester, New York 
July 15th, 2019 
  
2 
 
The Dynamic Roles of Red Blood Cell in Microcirculation 
by 
Sitong Zhou 
 
 
Committee Approval: 
 
We, the undersigned committee members, certify that we have advised and/or supervised 
the candidate on the work described in this dissertation.  We further certify that we have 
reviewed the dissertation manuscript and approve it in partial fulfillment of the 
requirements of the degree of Doctor of Philosophy in Microsystems Engineering. 
 
 
 
______________________________________________________________________________ 
Dr. Jiandi Wan                                                     Date 
Assistant Professor, Chemical Engineering 
 
 
 
______________________________________________________________________________ 
Dr. Steven W. Day                                               Date 
Associate Professor, Biomedical Engineering 
 
 
 
______________________________________________________________________________ 
Dr. Michael Schrlau                                                                            Date 
Associate Professor, Mechanical Engineering 
 
 
 
______________________________________________________________________________ 
Dr. Blanca Lapizco-Encinas                             Date 
Associate Professor, Biomedical Engineering 
 
 
 
 
Certified by: 
 
 
______________________________________________________________________________ 
Dr. Bruce Smith                     Date 
Director, Microsystems Engineering Program  
 
 
3 
 
ABSTRACT 
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Dissertation Title:  The Dynamic Roles of Red Blood Cell in Microcirculation 
 
 
Erythrocytes (otherwise known as red blood cells (RBCs)), are the most common 
cell type in the body. They are responsible for oxygen (O2) transportation as well as carbon 
dioxide (CO2) exchange. Different from most cells, red cells have no nuclei in mammals 
due to the enucleation during the maturation. The structure of erythrocytes was shown to 
have a phospholipid bilayer membrane, membrane proteins and cell skeleton. It provides 
the stability that RBCs need for the circulation in the body systems. Also, this well-
established structure makes it possible for them to accomplish ion and gas exchange, which 
therefore keeps the osmolality and pressure stable for extracellular and intracellular 
environment. Although a great variety of red cell characteristics have been investigated, 
the mechanism and kinetics of RBCs under certain environmental stimulation have not 
been well studied. In this work, we studied the development of cell membrane by testing 
the deformability change of erythrocytes during maturation. With the design of our 
microfluidic channels in ex vivo experiments, we then learned that RBC can work not only 
as O2 transporter but also as oxygen sensor itself. When oxygen level decrease, TBC 
membrane becomes softer and leads to blood flow increase eventually. We then 
investigated the mechanism of RBC membrane change on a molecular level to study the 
mechanism of RBC deformability change under hypoxia. We matched our findings in both 
in vivo and ex vivo experiments. Via in vivo experiments, we could even connect cerebral 
circulation to neuroactivity. Furthermore, the behavior of RBCs under hypoxia and in shear 
flow, such as the ATP release, was studied as well via ex vivo experiments. In the study, 
we focused on the mechanosensitive channel Piezo1 on RBC membrane and found the 
connection between this ion channel and RBC ATP release. 
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1. INTRODUCTION 
1.1. Maturation and circulation of erythrocytes 
RBCs comprise the most common cell type in the body transporting oxygen and 
carbon dioxide [1-3]. It was recognized that mature RBCs in mammals do not contain 
nucleus [1]. Research has shown the presence of two distinct populations of erythrocytes, 
primitive and definitive [2]. Figure 1-1 shows the overview of both primitive and definitive 
erythropoiesis [1], in which orthochromatic erythroblasts (OrthoE) enucleate to form a 
pyrenocyte that containing a condensed nucleus. After enucleation, it develops into a 
reticulocyte (Retic), which eventually matures into an RBC.  
 
 
Figure 1-1. Scheme of development of primitive and definitive erythropoiesis. The first blood cells 
in mammalian emerge within yolk sac, as known as primitive erythroblasts, while definitive cells 
occur in fetal live as well as postnatal bone marrow. [1] 
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Unlike the definitive erythropoiesis, which is observed in the fetal liver and the 
postnatal bone marrow, primitive erythroblasts are only found in the embryo [4-6], which 
are essential to the regeneration of erythrocytes and fetal development. The primitive 
erythroid lineage arises in the yolk sac, and pools of immature erythroblasts in “blood 
islands” are first apparent at the embryonic day of 7.25–7.5 (which is marked as E7.0–7.5) 
[4]. The number of primitive erythroid cells increases significantly within a vascular plexus 
at E8.0 [4, 7]. Different from definitive cells that enter the circulation after maturation, 
these large, immature, nucleated primitive cells move into the distal region of yolk sac and 
enter circulation beginning at E8.25, with the onset of cardiac contractions [3-10]. 
Primitive erythroblasts experience shear stresses in the fetal bloodstream as they travel 
through the embryonic microvasculature that has a diameter from 4 µm to 60 µm [11]. 
With the ability to squeeze through capillaries, the structure, composition and 
deformability of the cytoskeletal network in erythrocytes are well established.  
 
1.2. Structure of RBC membrane and cytoskeleton 
Mature RBC is biconcave-shaped, it composes of three major structural elements: 
lipid bilayer, integral proteins and cytoskeleton [12]. The lipid bilayer is primarily 
composed of phospholipids and cholesterol with permeability barrier for external 
environment and red cell cytoplasm exchange. It comprises about 50 to 60% mass of red 
blood cells, and phospholipids and cholesterol are almost equal amount [12]. The integral 
proteins are embedded in the membrane. RBC membrane proteins can be classified into 
transmembrane and peripheral proteins [13]. Common transmembrane proteins include 
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glycoprotein band 3, glycophorins, and protein 4.2 and so on. And there are peripheral 
membrane proteins including spectrin and ankyrin, etc. [12]. 
The RBC membrane skeleton is on the inner side of the cell membrane and it 
provides the structural integrity to the cell. The major components include spectrin, actin, 
ankyrin, and protein 4.1, etc. Spectrin is the most abundant in RBC membrane skeleton, 
consisting two subunits, α and β [12]. Together with erythrocyte membrane, the proteins 
and cytoskeleton provide the unique deformability and stability of red blood cells [12].  
 
1.3. Blood flow dynamics 
Fluid comes from Latin word meaning “to flow”. A fluid is usually defined as a 
substance that can flow, such as gas and liquid [14]. Besides pressure, density and 
temperature, etc., viscosity is one of the most important variables that characterizes specific 
fluid mechanical behavior. Viscosity is defined as the quantitative measure of a fluid’s 
resistance to flow [14]. For some common fluids as water or oil, there is a linear relation 
between the shear stress applied and resulting strain rate, as shown in Figure 1-2 [14]: 
𝜏 ∝
𝛿𝜃
𝛿𝑡
                                                           (1) 
For Newtonian fluid, the viscosity remains constant under certain temperature and it has 
nothing to do with the applied shear stress, which follows the equation: 
𝜏 = 𝜇
𝑑𝜃
𝑑𝑡
                                                        (2) 
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in which µ is the viscosity coefficient [14] (Figure 1-3). On the contrary, if the viscosity of 
the fluid changes over different applied shear stress, the fluid is then called non-Newtonian 
fluid. 
 
For the fluids with viscosities that increase with increasing strain rate, they are 
classified as shear-thickening fluids, which is also named dilatant [14]. On the contrary, 
shear-thinning fluid, however, has less resistance while the shear rate increases. It is called 
pseudoplastic [14]. Blood is known as pseudoplastic (shear-thinning) fluid, and the 
viscosity of normal whole blood as a function of shear strain rate has been previously 
investigated (Figure 1-4) [15]. Noted that in Cho’s study [15], all the measurements were 
conducted when hematocrit was in the range of 33% to 45%. Figure 1-4 [15] summarized 
the experimental results from different work with different symbols, while the lines were 
the predictions from a numerical simulation of various models [15]. From Figure 1-4 we 
can tell that within a great range of shear rate change, blood viscosity decreases when shear 
rate is getting higher. 
Figure 1-2. Shear stress causes continuous shear deformation in a fluid with a shear rate at δθ/δt. 
[14] 
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It was also shown that whole blood viscosity can be affected by a lot of factors 
including hematocrit, male or female, temperature, cholesterol level, and even smoking 
status, etc. [15]. Hematocrit has been shown to be the factor of changing blood viscosity. 
 
Figure 1-3. Relationship between shear stress and shear strain rate for both Newtonian (blue line) 
fluids (viscosity is constant at same temperature and pressure, when applied shear changes) and 
non-Newtonian fluids (viscosity changes when shear rate varies). Red line shows pseudoplastic 
fluid with decreasing viscosity when shear strain rate is higher. Contrarily, dilatant fluid’s viscosity 
increases with increasing shear strain rate (in green). 
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Generally, the higher hematocrit would end with greater blood viscosity, and the 
relationship can be expressed by the polynomial equation 
𝜂 = 1.4175 + 5.878𝐻 − 15.98𝐻2 + 31.964𝐻3                            (3) 
in which ƞ is the viscosity of blood in Poise, while H is the hematocrit (%) divided by 100 
[15]. And normally blood hematocrit is about 40%.  
Due to the large surface-to-volume ratio of RBCs, they have high stretch ability 
and also it was investigated that the membrane of erythrocytes can have tank tread-like 
motion in shear flow [16-18]. With the elasticity of cell membrane and the tank treading 
motion of RBCs, deformability is a critical characteristic of RBCs and it involves a variety 
of physiological process, such as cation transport [19], ATP release [20, 21], etc. Among 
all the functions, oxygen transportation of RBCs [22, 23] is most known with oxygen 
Figure 1-4. Blood viscosity changes over the change of shear rate. Hematocrit was in the range of 
33% to 45% for all the measurements. All the symbols represented the viscosity data measured 
experimentally by different studies, while the dashed lines and solid lines showed the predictions 
from different models. [15] 
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binding with hemoglobin (Hb) inside erythrocytes. RBC is the major supplier of oxygen, 
delivering oxygen from lungs to all the tissues in the body. 
 
1.4. Goals, tasks and content of work 
In this study, the dynamic roles of RBCs in microcirculation was investigated in 
multiple perspectives. 
Object 1 Role of RBC in cerebral circulation in the process of functional 
hyperemia: In vivo and ex vivo experiments were performed to verify that RBC played an 
important role in regulating blood flow velocity when oxygen level changed. It was found 
that RBC can not only work as O2 transporter but also O2 sensor as they became more 
deformable under hypoxia.  
Object 2 Assessment of the mechanism of how O2 mediated RBC membrane 
deformability: To study erythrocyte response under hypoxia, RBCs from transgenic mice 
were used to study the process of RBC membrane modification under hypoxic condition. 
With both in vivo and ex vivo experiments, it can be demonstrated that the membrane 
protein interactions were the key of how RBCs became more deformable when O2 
decreased. 
Object 3 Evaluation of the role of mechanosensitive channel Piezo1 on ATP 
release from RBCs: to study the behavior of RBC under hypoxia and in shear flow, we 
focused on ATP release from RBC. Since ion channel Piezo1 was known to be activated 
under shear stress, ex vivo experiments were conducted to investigate how Piezo1 can 
affect ATP release by regulating calcium influx in RBCs. 
14 
 
Object 4 Investigation of the importance of maturation stage to RBC membrane 
deformability: To understand the importance of certain cell membrane protein 
development, RBC deformability at different maturation stages was tested via ex vivo 
experiments to provide further understanding of the role of RBC in microcirculation in the 
embryo stage.  
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2. ERYTHROCYTES ARE OXYGEN-SENSING 
REGULATORS OF THE CEREBRAL 
MICROCIRCULATION 
Energy production in the brain depends almost exclusively on oxidative metabolism. 
Neurons have small energy reserves and require a continuous supply of oxygen (O2). It is 
therefore not surprising that one of the hallmarks of normal brain function is the tight 
coupling between cerebral blood flow and neuronal activity. Since capillaries are 
embedded in the O2-consuming neuropil, we here examined whether activity-dependent 
dips in O2 tension drive capillary hyperemia. In vivo analyses showed that transient dips in 
tissue O2 tension elicit capillary hyperemia. Ex vivo experiments revealed that RBCs 
themselves act as O2 sensors that autonomously regulate their own deformability and 
thereby flow velocity through capillaries in response to physiological decreases in O2 
tension. This observation has broad implications for understanding how local changes in 
blood flow are coupled to synaptic transmission. 
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2.1. Introduction 
Neurovascular coupling involves synaptic activity linking to local changes in 
cerebral blood flow [24, 25]. The mechanisms by which neural activity triggers hyperemia 
have been extensively studied because neurovascular coupling forms the basis for 
functional brain imaging. In addition, defects in neurovascular coupling may contribute to 
cognitive decline in neurodegenerative diseases, such as Alzheimer disease, as well as in 
hypertension and stroke [26].  
Functional hyperemia can be mediated by a number of compounds, many of which 
are byproducts of neural activity, including adenosine, nitric oxide (NO), potassium ions 
(K+), and carbon dioxide (CO2) [24]. In addition, functional hyperemia is preceded by a 
transient decrease in tissue oxygenation [27-29]. Since recent reports have documented that 
functional hyperemia is initiated in micro vessels embedded in the O2-consuming neuropil. 
The present study investigated whether RBCs can work as O2 sensor and whether the initial 
dip in tissue O2 tension drives brain capillary hyperemia. [30] 
 
2.2. Experimental methods 
2.2.1. Animals and surgical preparation 
C57BL6 mice (25–30 g, 8–12 weeks old, The Jackson Laboratory) of either sex 
were utilized. Mice were prepared for in vivo imaging as described previously [31-34]. All 
experimental procedures were approved by the University Committee on Animal 
Resources at the University of Rochester and effort was taken to minimize the number of 
animals used. Anesthesia was induced in experimental animals with 3.0% isoflurane in 
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room air and maintained at 1.5-2.0% during surgical preparation. Depth of anesthesia was 
monitored by toe-pinch, or blood pressure. Body temperature was maintained by a water 
perfused thermal pad (Gaymar T/Pump) set at 37°C. A custom-made metal plate was glued 
to the skull and a 2-3 mm diameter cranial window was made over the hindlimb cortex for 
imaging (stereotaxic coordinates: 0.5–3 mm lateral; −1.5 to +1 mm anterior of bregma). 
Agarose (0.8% in artificial CSF (aCSF), 37˚C) was applied and a glass coverslip was sealed 
to the metal plate [31, 33]. In hindlimb stimulation experiments, mice were intubated and 
mechanically ventilated with a small animal ventilator (SAAR-830) in series with an 
isoflurane vaporizer, and a femoral artery was cannulated for blood gas and blood pressure 
measurements. Blood gas parameters were maintained within physiologic limits for all 
experiments. In habituated mice that were allowed to awaken after surgery and prior to 
imaging, only a cranial window was prepared [32, 34]. 
 
2.2.2. Physiological manipulation 
In hindlimb stimulation experiments, anesthesia was reduced to 1% isoflurane 
immediately prior to experimentation. Blood pressure was continuously monitored to 
assess depth of anesthesia. Hindlimb stimulation was delivered using 2 ms square-wave 
pulses at an intensity of 0.5-1.0 mA (ISO-flex, A.M.P.I.) in a 2 s 10 Hz train, controlled by 
a Master-8 and captured with Clampex 9.0 [35]. Stimulus intensity was titrated in each 
animal to avoid increases in mean arterial blood pressure in response to sensory 
stimulation. 
In O2 scavenging experiments, 0.001-1.0 M sodium sulfite was dissolved in water 
containing 100 μM Alexa Fluor 594, loaded into glass micropipettes with tip diameters of 
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2-3 μm, and puffed onto vessels for 100 ms at 10 psi, controlled by a Picospritzer III. In 
the O2 scavenging experiments, mice were habituated to restraint tubes prior to the 
experiment and allowed to awaken from anesthesia before experimental manipulations [32, 
34]. 
 
2.2.3. Microfluidic device and RBC imaging 
Microfluidic chips were fabricated with polydimethylsiloxane (PDMS) using 
standard soft photolithography techniques [17, 36, 37]. The widths of the introduction and 
constriction segments of the capillary channel were 78 μm and 5 μm (Figure 2-2A), 
respectively. The channel height was 7 μm as measured with a surface profilometer (KLA 
Tencor P2). The microfluidic device was connected via a short polyethylene (PE 20) tube 
to an RBC reservoir where a constant pressure (1.6 psi) was applied by using a gas regulator 
(Omega, DPG1001B) with a precision of 0.1 psi. 
To colorimetrically quantify the O2 partial pressure (PO2) in the capillary channel, 
25 μM of tris(2,2'-bipyridyl)dichlororuthenium(II) hexahydrate (Sigma-Aldrich) was 
prepared in N2-bubbled or air-saturated deionized (DI) water. The dye solution was injected 
into the microfluidic device, which was immersed in a customized glass chamber filled 
with H2O or sulfite solution. 
To create an O2 sink, sodium sulfite (Sigma-Aldrich, 0.01, 0.1, 1.0, 1.5, or 2.0 M) 
was added to the chamber. The change in fluorescence intensity of the O2 indicator flowing 
through the microfluidic device at 1.6 psi exposed to 0.0, 0.01, 0.1, 1.0, 1.5, and 2.0 M 
sodium sulfite (NaSO3) was measured using a RatioMaster system (Photon Technology 
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International) and converted to a PO2 value using the Stern-Volmer equation, 𝐼0 − 𝐼 = 1 +
𝑃𝑂2 × 𝐾𝑞, in which I0 is the maximum of the fluorescence intensity and Kq is the quenching 
constant. Because PO2 in N2-bubbled dye (after bubbling for 16 hours) and air-saturated 
dye was 34 mmHg and 174 mmHg, respectively (measured and calibrated using a World 
Precision Instruments dissolved O2 meter and a Bayer RAPIDLab 248 blood gas analyzer), 
these values of I0 and Kq were used to calculate PO2 in microfluidic channels, I0 = 21129.5 
and Kq = 0.00262501. 
Human RBCs were collected from healthy donors and prepared on the day of use. 
The RBCs were separated from plasma by centrifuging 3 mL of blood at 500 rcf at 20°C 
for 1.5 minutes. The supernatant was removed by aspiration. The packed RBCs were 
resuspended and washed three times in PBS buffer. The RBCs were then diluted with a 
PBS solution (3%, v/v) that in some experiments had been bubbled with N2 overnight. The 
resuspended RBCs were introduced into the microfluidic channel. Apyrase (40 U/mL), L-
NAME (3 mM), CNQX (200 μM), or diamide (200 μM) was added to the PBS in some 
experiments. In some experiments, potassium channel inhibitors (4-aminopyridine (4-AP, 
1 mM), charybdotoxin (100 nM), or iberiotoxin (100 nM)) were used to treat RBCs for 5 
to 10 minutes before the RBCs were introduced into the microfluidic channel. 
To measure RBC velocity during exposure to various PO2 conditions (sodium 
sulfite at 0.0, 0.01, 0.1, and 1.0 M), RBCs were injected into the device and pushed through 
the constriction channel at a constant pressure of 1.6 psi using a gas regulator (Omega 
DPG1001B) with a precision of 0.1 psi. The movements of single RBCs in the introduction 
and constriction segments of the channel were recorded using a high-speed video camera 
(Phantom Miro M120, 1900 frames per second) mounted on an inverted microscope (Leica 
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DMI 6000B). The velocities of RBCs were obtained by analyzing the video using Phantom 
Camera Control software. The velocity of RBCs moving through the 1 mm-long 
introduction channel was 4.6061 mm/s ± 0.8358 mm/s. Prior to entering the constriction 
channel where RBC velocity and deformation were quantified, RBCs had been exposed to 
the O2 sink for approximately 217 ms while flowing through the introduction channel. 
To determine the deformability of RBCs under various O2 tensions, we utilized a 
microfluidic device with a constriction channel of 20 μm in width and 100 μm in length. 
The deformation of RBCs flowing through the constriction channel was recorded using a 
high-speed video camera. The change in length (DL) and thickness (DW) of RBCs flowing 
through the constriction channel was obtained by analyzing the videos using Phantom 
Camera Control software. The normalized elongation index (DL/DW) was used to 
characterize the deformation of RBCs in flow. Deformation of RBCs treated with diamide 
(200 μM) or potassium channel inhibitors (4-AP (1 mM), charybdotoxin (100 nM), or 
iberiotoxin (100 nM)) was also examined. 
 
2.2.4. Intrinsic optical signal and two-photon imaging 
Intrinsic optical signals (IOS) were captured at 52 frames per second with a 12-bit 
INFINITY2-1M CCD camera by custom-made MATLAB software as previously 
described [35]. A green (570 nm) light filter was used to image total changes in blood 
volume [38]. Two-photon imaging was performed using a custom-built microscope 
attached to a MaiTai HP Ti:Sapphire laser (Spectra Physics), a scan box controlled by 
FluoView software (FV300, Olympus), and a 20x objective (0.9 NA, Olympus). 
Intravascular fluorescein isothiocyanate-dextran (FITC-dextran) and intra-micropipette 
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Alexa Fluor 594 were excited at 820 nm. Midline arteriole and capillary RBC flow 
velocities within the activated hindlimb cortex identified by IOS were captured with line 
scans (scan rate ~1 kHz) placed along the length of the vessel. Vessel diameters were 
captured with line scans placed perpendicular to the axis of blood flow [39]. 
 
2.2.5. Two-photon image analysis 
RBC velocities (= Δx/Δt, mm/s) were calculated from parallel-to-flow line scan 
images using the contrast between FITC-dextran-labeled plasma and unlabeled RBCs, 
using a modified version of the LS-PIV algorithm in MATLAB described elsewhere [40]. 
Vessel lumen diameters were calculated from perpendicular-to-flow line scan 
images using the contrast between the unlabeled tissue outside blood vessel lumens, 
unlabeled RBCs, and FITC-dextran-labeled plasma. As areas outside the capillary lumen 
were black, RBCs grey, and plasma white, capillary/vessel edges were determined by 
fitting sigmoidal curves to each edge and the diameter taken to be full width at half-
maximum. This method provides increased accuracy due to subpixel resolution and 
robustness to artifacts as compared to simply setting a fixed threshold. 
 
2.3. Results and discussions 
To identify the brain region activated by hindlimb stimulation, the exposed cortex 
was visualized using IOS and high-speed two-photon line scan, which gives the 
information of RBC velocity in both arterioles and capillaries in the contralateral sensory 
cortex of lightly sedated mice (Figure 2-1A) [35, 39].  
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Only cortical arterioles and capillaries located in the cortical region that exhibited 
the largest activity-dependent increase in IOS were analyzed. A comparison of the onset 
time of stimulation-induced elevation in RBC velocity revealed that capillary RBC 
velocities (0.67 ± 0.15 s, n = 65, 25 mice) increased prior to RBC velocities of upstream 
arterioles (2.33 ± 0.22 s, n = 61, 25 mice) (Figure 2-1B), which is consistent with 
conclusions drawn by a prior study on vascular diameters [41]. The results of capillary 
diameter change (not shown) further proved that activity-dependent increases in capillary 
RBC velocities occur prior to both dilations of and RBC velocity increases in upstream 
arterioles, indicating that capillary hyperemia occurs before arterial hyperemia. 
Figure 2-1. PO2 Dips Are Necessary to Elicit Capillary Hyperemia. (A) Experimental setup for 
assessing functional hyperemia elicited by sensory stimulation. Arterial blood pressure was 
monitored through a femoral artery catheter while the other hindlimb was stimulated. Through a 
cranial window, intrinsic optical signaling (IOS) was used to identify the cortical region of 
functional hyperemia. LFP and O2 sensor microelectrodes were placed in close proximity (10–20 
µm) to one another within the activated region. During hindlimb stimulation, blood vessels in the 
activated contralateral hindlimb cortex were imaged using two-photon laser scanning microscopy. 
(B) Time-course plot of hindlimb stimulation-evoked RBC velocity changes in cortical arterioles 
(red) and capillaries (black). Inset: IOS imaging (shown as a pseudocolor image) was used to 
identify the location of the activated hindlimb cortex in all experiments. Scale bar, 300 mm. Evoked 
RBC velocity increases began in capillaries (0.67 ± 0.15 s) prior to arterioles (2.33 ± 0.22 s). n = 
61–65, 25 mice. [30] 
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The observation that microinjection of O2 scavengers induced pericyte- and 
vasoactive mediator-independent capillary hyperemia led us to hypothesize that O2 tension 
itself, independent of the neurovascular unit, can control RBC deformation and thus RBC 
flow through capillaries. To test this idea in the absence of the neurovascular unit, we 
turned to an ex vivo assessment of the effect of oxygenation on RBC flow through an 
artificial capillary. We employed a microfluidic device in which isolated human RBCs pass 
through a narrow flow channel (Figure 2-2A) [17, 37, 42, 43]. This approach allowed an 
evaluation of RBC velocity in the absence of the cellular components of the neurovascular 
unit.  
 
Figure 2-2. Ex vivo experiments of velocity measurement under hypoxia. (A) A diagram of the 
experimental setup for ex vivo analysis of the effect of PO2 on RBC flow velocity. Human RBCs 
were added to the bath containing PBS and forced to flow through a microfluidic device containing 
a narrow channel by applying a constant pressure (1.6 psi). The microfluidic device was submerged 
in an O2 sink (chamber containing H2O with 0.0, 0.01, 0.1, or 1.0 M sodium sulfite). PO2 in the 
microfluidic channel was successively lowered by increasing the concentration of sulfite in the O2 
sink (0.0–1.0 M). RBC motion was captured by a high-speed camera. (B) Left: colorimetrically 
quantify PO2 in the capillary channel. The change in fluorescence intensity of the O2 indicator dye 
solution flowing through the microfluidic device was measured during exposure to 0.0, 0.01, 0.1, 
1.0, 1.5, and 2.0 M sodium sulfite solution and converted to PO2. Right: images comparing RBC 
flow within an O2 sink containing 0 or 1 M sulfite. Images of flowing RBCs captured by the high-
speed camera at sequential time points are superimposed. Error bar: 5 µm. 
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Figure 2-3. (A) Lowering PO2 in the microfluidic channel caused an increase in RBC velocity. (B) 
Dephosphorylation of extracellular ATP or inhibition of NOS and AMPA receptors did not alter 
RBC velocity increases in response to lowering surrounding PO2. When diamide was added to 
stiffen RBC membranes, lowering PO2 failed to increase RBC velocity compared to controls. (C) 
In the presence of the potassium channel inhibitors the sensitivity of RBC velocity to the change in 
PO2 was reduced. (D) A schematic of the experimental setup for ex vivo analysis of the effect of 
PO2 on RBC deformability. (E) The elongation index (DL/DW) of RBCs changed over O2 level 
change. (F) Elongation indexes (DL/DW) of control RBCs and RBCs treated with potassium 
inhibitors at different O2 tensions. 
A B 
C D
E F 
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Since the capillary lumen is considerably smaller than RBC diameters, RBC 
deformability is a major determinant of the speed by which the RBC passes through a 
capillary [44]. The microfluidic device made of PDMS was submerged in a chamber 
containing sodium sulfite, an O2 scavenger. Since PDMS is O2, but not H2O, permeable 
the chamber functioned as a sink for O2 (Figure 2-2A). A colorimetric calibration, based 
on adding the O2-sensing dye tris(2,2’-bipyridyl)dichlororuthenium(II) hexahydrate to 
deionized (DI) water showed that PO2 in the flow channel was an inverse function of the 
sulfite concentration (0 to 2 M) (Figure 2-2B). Remarkably, the velocity of RBCs flowing 
through the channel increased as a function of O2 depletion, indicating that brief 
deoxygenation alone can affect the mechanical properties of RBCs (Figures 2-2B and 2-
3A). The O2-dependent increase in RBC velocity was observed when RBCs were 
resuspended in either plasma or PBS (Figure 2-3A). We focused on the effects of relatively 
lower PO2. In these experiments, the PBS was first purged with N2 until the PO2 reached 
34 mmHg, approximating normal brain PO2 [45]. Similar to above, RBCs were driven 
through a microfluidic chamber immersed in a sulfite sink (0 to 1M) and colorimetrically 
calibrated (Figure 2-2B). This analysis showed that at a relatively lower range of O2 
tension, RBC velocities became more sensitive to surrounding changes in PO2 (p < 0.001, 
t test with Bonferroni test, compared to PBS without N2 purging and plasma) (Figures 2-
3A and 2-3B). Interestingly, however, increasing the O2 from 21% to 100% (or from PO2 
~160 mmHg to ~760 mmHg) failed to alter RBC velocity in the microfluidic capillary 
(1.000 normalized velocity in 21% versus 0.998 normalized velocity in 100% O2, n = 9–
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19, p > 0.05, t test), consistent with the notion that at super physiologic PO2, hemoglobin 
continues to be maximally saturated with O2 and RBCs reach the limit of their ability to 
bind additional O2 and respond with velocity changes. 
We also found that the PO2-elicited increase in RBC flow velocity was not a result 
of direct ATP or NO release. Exposing RBCs to the ATP-degrading enzyme apyrase (40 
U/mL) or the NO synthase inhibitor L-NAME (3 mM) did not affect PO2-induced 
elevations in RBC velocity (Figure 2-3B), in accordance with the in vivo observation that 
L-NAME failed to suppress capillary hyperemia (data not shown). In addition, CNQX had 
no effect on PO2-induced increases in RBC velocity through the microfluidic channel 
(Figure 2-3B). When RBCs were treated with K+ channel inhibitors (4-AP [non-selective 
voltage-dependent K+ channel blocker, 1 mM], charybdotoxin [Ca2+-activated voltage-
gated K+ channel blocker, 100 nM], or iberiotoxin [large-conductance Ca2+-activated K+ 
channel blocker, 100 nM]), however, the sensitivity of RBC velocity to PO2 changes 
decreased (Figure 2-3C), suggesting that K+ flux across the membrane plays a role in the 
velocity of RBC flow in capillaries. As a negative control, RBCs were treated with diamide, 
which stiffens the RBC membrane by crosslinking the cytoskeletal spectrin network [17]. 
The flow velocity of diamide exposed RBCs was unaffected by PO2, supporting the notion 
that the PO2-induced increase in RBC flow velocity is due to increased deformability of 
the RBC membrane (Figure 2-3B). To directly test whether RBC deformability is 
controlled by PO2, we assessed the shear-induced deformability of RBCs flowing in a 
relatively large-sized microfluidic channel containing a segment of constriction (width = 
20 µm) (Figure 2-3D). 
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The shear induced deformability of RBCs was characterized by the elongation 
index DL/DW, where DL and DW represented the length and thickness of an RBC flowing 
through the constriction, respectively. We found that the elongation of RBCs in response 
to shear stress increased as PO2 decreased, demonstrating that RBCs are more flexible in 
lower PO2 conditions (Figure 2-3E). The dependence of RBC deformability on PO2 was 
significantly diminished when diamide was added (Figure 2-3E). RBCs treated with the K+ 
channel blockers 4-AP (1 mM), charybdotoxin (100 nM), or iberiotoxin (100 nM) also 
exhibited reduced sensitivity to PO2 changes compared to controls (Figure 2-3F). These 
data show that lowering PO2 increases RBC deformability and thereby the velocity by 
which RBCs pass through a narrow ex vivo capillary lacking endothelial cells, pericytes, 
and astrocytes. Exposure to K+ channel inhibitors reduced the deformability of RBCs and 
thus the potency by which PO2 increased RBC flow velocity. This latter observation is 
consistent with prior studies documenting that a decrease in cell volume mediated by K+ 
efflux and water loss may play a role in permitting RBC deformation during the shear stress 
associated with squeezing through a narrow capillary [43]. 
 
2.4. Conclusion 
Functional hyperemia is an integrated response that tightly couples O2 consumption 
with O2 supply. Here we show that both spontaneous and activity-induced dips in tissue 
PO2 drive the earliest phase of capillary hyperemia. Furthermore, PO2 directly controls the 
velocity by which RBCs transit through a narrow channel in a microfluidic device. Thus, 
RBCs may themselves serve as autonomous regulators of capillary perfusion that operate 
independently of the neurovascular unit and the release of vasoactive molecules. The idea 
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that erythrocytes—the major suppliers of O2—function not only as O2 carriers but also as 
O2 sensors and regulators of capillary blood flow provides a simple, yet swift and precise, 
mechanism for controlling the cerebral microcirculation. 
29 
 
3. OXYGEN TENSION–MEDIATED ERYTHROCYTE 
MEMBRANE INTERACTIONS REGULATE 
CEREBRAL CAPILLARY HYPEREMIA 
We demonstrated previously that cerebral functional hyperemia is initiated in brain 
capillaries and RBCs act as act as oxygen sensors to increase their deformability and flow 
velocity in response to local oxygen tension (PO2) drop in the brain [30]. However, it 
remains unclear how RBC membrane mechanics change in response to PO2 drop and how 
RBC deformability relates quantitatively to RBC velocity in capillaries. Here, we 
combined ex vivo microfluidic approaches with in vivo two-photon imaging techniques  
and studied mechanistically PO2-regulated RBC dynamics in capillary using transgenic 
mice with modified deoxyHb-band 3 interaction. In particular, we showed that 1) the  
capillary velocity and shear-induced elongation of RBCs from transgenic mice with either 
increased or decreased deoxyHb-band 3 interaction lose the sensitivity to local PO2 change 
in microfluidics; 2) chemical modification of deoxyHb-band 3 interaction in human and 
wild type mice RBCs also can manipulate the PO2-regulated capillary velocity and shear-
induced elongation in microfluidics; 3) in vivo capillary velocity of RBCs in transgenic 
mice with modified deoxyHb-band 3 interaction showed impaired responses to PO2 
changes; 4) RBC velocity and tank-treading frequency depend on the duration of PO2 
exposure and a lubrication model relates RBC membrane tension to velocity in 
capillary.[46] 
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3.1. Introduction 
Thinking, reading, writing, or throwing a baseball are all activities in which neural 
activity is coupled with local elevation in cerebral blood flow (CBF). The mechanisms by 
which neural activity triggers hyperemia have been extensively studied, in part, because 
neurovascular coupling forms the basis for functional brain imaging [47, 48]. Defects in 
neurovascular coupling are also believed to contribute to cognitive decline in 
neurodegenerative conditions such as Alzheimer disease, as well as in hypertension and 
stroke [26]. Despite the uncontested tight linkage between neural activity and 
cerebrovascular responses, the question of what drives functional hyperemia is still unclear.  
 
 
Figure 3-1. PO2 dips can trigger capillary hyperemia. (A) Left panel is the scheme of the 
experimental setup to puff O2 scavenger around the capillary and study the local effect. The right 
panel is the results of local O2 dip after applying O2 scavenger. (B) RBC velocity increase in the 
capillary after microinjection of O2 scavenger. [30] 
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Most recently, it has emerged that functional hyperemia is initiated in the smallest 
blood vessels in brain, capillaries, where activity-driven decreases in tissue oxygen tension 
(PO2) directly increase the velocity of RBCs measured both in vivo and ex vivo, as shown 
in Figure 3-1 [30]. Analysis in microfluidic chambers, in which RBC velocity can be 
studied in the absence of the neurovascular unit, shows that changes in PO2 can directly 
trigger an increase in RBC flow velocity by increasing RBC deformability, thus decreasing 
vascular resistance [30]. As such, RBCs are active players in capillary hyperemia, and 
promptly increase O2 delivery in response to activity-induced local changes in PO2. Such 
RBC mediated capillary hyperemia thus provides a simple yet robust mechanism for swift 
and precise local increases in capillary flow in response to the ever-changing patterns of 
neural activity within the central nervous system (CNS). These observations, however, also 
prompt a new line of questions. For example, what is the molecular mechanism that 
regulates RBCs’ responses to the change of PO2? How quantitatively does the RBC 
capillary velocity relate to its deformability? What is the dynamics of PO2-regulated RBC 
capillary velocity? 
Previous studies have shown that PO2 is a potent regulator of multiple RBC 
activities including glucose metabolism [49, 50], cation transport [19], ATP release [20, 
21] and cytoskeletal organization [21, 51-53]. In particular, the reversible binding of 
deoxygenated hemoglobin (deoxyHb) with band 3 has been postulated to be critical in 
many of these processes because the cytoplasmic domain of band 3 contains the only 
known hemoglobin (Hb) binding site on the RBC membrane and Hb-band 3 interaction is 
strongly O2-dependent [54-56]. As indicated in Figure 3-2 [51], increased deoxyHb-band 
3 interaction at decreased PO2, for example, reduces the band 3-ankyrin interaction on the 
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RBC membrane, resulting in a mildly weakened membrane [51]. Whether and how such 
changes will affect RBC deformability and velocity in capillary, however, is unclear. Here, 
we hypothesize that deoxyHb-band 3 interaction during RBC deoxygenation induces the 
displacement of ankyrin from band 3, which leads to a more deformable RBC membrane 
and thus an increased capillary velocity. 
 
 
To test the hypothesis, we have combined ex vivo microfluidic approach and in vivo 
two photon laser scanning microscopy to measure RBC deformability and capillary 
velocity at controlled PO2. Results from wild type mice and transgenic mice that have 
Figure 3-2. The accessibility of ankyrin increases with the deoxygenation of human RBCs. The 
right-hand panel indicates that the intensity increased after deoxygenation of stained human RBCs, 
showing the increased accessibility of ankyrin, which proves the decreased interactions between 
ankyrin and band 3. Error bar: 10 µm. [51] 
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modified RBC deoxyHb-band 3 interactions are obtained. Additionally, we show 
pharmacological manipulations of the deoxyHb-band 3/band 3-ankyrin interaction in 
RBCs from wild type mice and human to control the capillary RBC velocity and 
deformability in response to reduced PO2. Lastly, the dynamics of PO2-regulated RBC 
capillary velocity are investigated and a critical PO2 exposure time is proposed. 
 
3.2 Experimental methods 
3.2.1 Animals and surgical preparation 
Three strains of transgenic mice (mRBC-subst 1-35, mRBC-del 1-11, and mRBC-
del 12-23) were kindly provided by the David Bodine lab from NIH. Wild type mice 
(mRBC-WT, C57BL/6J) were purchased from the Jaskson Lab. Anesthesia was induced 
in experimental animals with 3.0% isoflurane in room air and maintained at 1.5-2.0% 
during surgical preparation. Depth of anesthesia was monitored by toe-pinch, or blood 
pressure. Body temperature was maintained by a water perfused thermal pad (Gaymar 
T/Pump) set at 37°C. A custom-made metal plate was glued to the skull and a 2-3 mm 
diameter cranial window was made over the hindlimb cortex for imaging (stereotaxic 
coordinates: 2 mm lateral; 2 mm anterior of bregma). Agarose (0.8% in artificial CSF 
(aCSF), 37˚C) was applied and a glass coverslip was sealed to the metal plate [31, 33]. 
All experimental procedures were approved by the University Committee on 
Animal Resources at the University of Rochester and effort was taken to minimize the 
number of animals used. 
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3.2.2 RBC preparation and treatment 
Whole blood was extracted from healthy human donors or wild type and transgenic 
mice and prepared on the day of use. RBCs were separated from plasma by centrifuging 1 
mL of whole blood at 500 g at 20°C for 1.5 minutes. The supernatant was removed by 
aspiration. The packed RBCs were resuspended and washed three times in PBS buffer. The 
RBCs were then diluted with a PBS solution (3%, v/v) that in some experiments had been 
bubbled with N2 overnight. Note that for mRBCs, PBS was prepared as follow: 152 mM 
NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 KH2PO4, and 10 mM glucose, pH = 7.4, 
Osmolality: 340 mOsm/Kg; For human RBCs, PBS was used as purchased from 
ThermoFisher Scientific (pH = 7.2, Osmolality: 280-320 mOsm/Kg, Catalog # 20012027). 
PEP (phosphoenolpyruvate)  and Pi (inorganic phosphate) solutions were prepared in PBS 
as follow [57]: PEP solution (PEP 50 mM, Mannitol 28.8 mM, glucose 50 mM, NaCl 20 
mM and adenine 1 mM) and Pi solution (sodium phosphate 50 mM, Mannitol 28.8 mM, 
glucose 50 mM, NaCl 20 mM and adenine 1 mM).  The pH of the solutions was adjusted 
to 6.0. Packed RBCs were suspended into either PEP or Pi solution and incubated for one 
hour at 37˚C and then washed twice with PBS [57]. To determine the concentration of 2,3-
DPG in RBCs, UV-testing was conducted following the manufacturing protocol of Sigma 
Kit (Sigma-Aldrich, catalog # 10148334001). In pervanadate treatment, packed RBCs 
were suspended in PBS with 0.5 mM sodium orthovanadate and 150 mM H2O2. After 
incubated at 37˚C for 30 mins, RBCs were washed three times using PBS and resuspended 
in a fresh PBS with glucose for 180 mins to obtain 100% phosphorylation of band 3 and 
ankyrin. 
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3.2.3 Microfluidic device and RBC imaging 
Microfluidic devices were fabricated with PDMS using standard soft 
photolithography techniques [17, 36, 37]. The microfluidic device was connected via a 
short polyethylene (PE 20) tube to an RBC reservoir where a constant pressure (1.6 psi) 
was applied by using a gas regulator (Omega, DPG1001B) with a precision of 0.1 psi. To 
control PO2 inside the channel, the entire microfluidic device was immersed in a 
customized glass chamber filled with an aqueous solution containing 0, 0.01, 0.1, or 1.0M 
of sodium sulfite (Sigma-Aldrich) and the PO2 inside the was equilibrated with the 
surrounding environment for 20 mins before experiments.   
PO2 calibration in microfluidics: To colorimetrically quantify PO2 in the microfluidic 
channel, 25 μM of tris(2,2'-bipyridyl)dichlororuthenium(II) hexahydrate (an O2 indicator, 
Sigma-Aldrich) was prepared in N2-bubbled or air-saturated deionized (DI) water and 
injected into the microfluidic device at a constant pressure (1.6 psi). The change in 
fluorescence intensity of the O2 indicator flowing through the microfluidic device was 
measured using a RatioMaster system (Photon Technology International) and converted to 
a PO2 value using the Stern-Volmer equation, I0 / I = 1 + PO2 × Kq, in which I0 is the 
maximum of the fluorescence intensity and Kq is the quenching constant. To calculate I0 
and Kq, we used PO2 of 34 mmHg and 174 mmHg respectively in N2-bubbled dye solution 
(after bubbling for 16 hours) and air-saturated dye solution, which was measured and 
calibrated using a World Precision Instruments dissolved O2 meter and a Bayer RAPIDLab 
248 blood gas analyzer. These values of I0 and Kq were then used to calculate PO2 in 
microfluidic channels.  
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RBC velocity and deformability measurement as a function of PO2: To measure mRBC 
velocity, we injected mRBCs into a microfluidic device with a constriction of wc = 3 µm 
and h = 4 µm at a constant pressure of 1.6 psi. The movements of mRBCs in the constriction 
were recorded by a high-speed video camera (Phantom Miro M120, 1900 frames per 
second) mounted on an inverted microscope (Leica DMI 6000B). The recorded videos 
were analyzed using Phantom Camera Control software and imagingJ and mRBC velocity 
was calculated assuming a steady flow condition. To determine the deformability of 
mRBCs, we utilized a microfluidic device with a constriction of wc = 10 µm and h = 7.4 
µm. The deformation of mRBCs flowing through the constriction was recorded using the 
high-speed camera and characterized by the change of elongation index DL / DW, where DL 
and DW is the length and thickness of mRBC respectively. 
 
Table 3-1. Dimensions of microfluidic channels in use for human RBC measurement 
Channel type (for human RBC) Overall height Width of constrction 
Velocity measurement 7 µm 5 µm 
Deformability measurement 30 µm 20 µm 
 
To examine human RBC velocity and deformation as a function of PO2, we used 
the same approach as described above expect that a microfluidic device with a constriction 
of wc = 5 µm and h = 7 µm and wc = 20 µm and h = 30 µm was used respectively for the 
hman RBC velocity and deformation meaasurement. To study the effect of total exposure 
time of reduced PO2 on RBC velocity, we used microfluidic devices with different lengths 
of channel before the constriction (100, 500, 1000, 1500, 3000, 5000, 7000 and 9000 µm) 
to control the total exposure time. In this case, the PO2 was controlled at 0 and 34 mmHg. 
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The data was then fitted using an exponential function 𝑦 = 𝑦0 + 𝐴𝑒𝑥𝑝(
−(𝑥−𝑥0)
𝜏
) where τ is 
the characteristic exponential time constant.  
RBC tank-treading frequency measurement: A microfluidic channel containing a 
constriction (wc = 20 μm and h = 38 µm) was used to measure tank-treading frequency of 
human RBCs. The microfluidic device was immersed in a sulfite sink with different 
concentrations of sodium sulfite (0, 0.01, 0.1, to 1 M). The length of the channel before 
constriction was varied from 600, 4200 to 12000 μm to obtain a total exposure time of 18 
± 4, 192 ± 30, and 377 ± 11 ms respectively. 1 mL human RBCs suspension in PBS (1.5 
% v/v) was mixed with 10 µL 1 µm polystyrene microspheres (0.5 % w/v in PBS, 
Polybead, Polysciences, Inc.) and injected into the microfluidic channel. Dextran (Sigma-
Aldrich, Leuconostoc spp. Mr 450,000-650,000) was added to increase the viscosity of 
RBC suspension from 1.36 mPa·s, 2.61 mPa·s, to 4.66 mPa·s as measured by a rheometer 
(Discovery HR-2 Hybrid Rheometer, TA Instrument). The rotation of the microbead on 
RBCs was recorded using a high-speed camera and the tank-treading frequency was 
calculated as 1/the time for the microbead moving along with the membrane for one 
revolution.  
 
3.2.4 In vivo two-photon imaging 
Two-photon imaging was performed using a Thorlab two-photon setup attached to 
a MaiTai HP Ti: Sapphire laser (Spectra Physics). A 20× objective (0.9 NA, Olympus) was 
used. Intravascular fluorescein isothiocyanate-dextran (FITC-dextran) (2.5% in saline) is 
injected from the tail of the mouse and excited at 820 nm. To prepare the sulfite puffing 
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solution, 0.01M or 1M sodium sulfite was dissolved in 10 mM HEPES (with a drop of HCl 
to adjust pH to 7.3) containing 100 μM Alexa Fluor 594 and loaded into a glass 
micropipette with a tip diameter of 2-3 μm. The puffing micropipette was then carefully 
loaded into a capillary bed in the cerebral cortex and the sulfite solution was puffed at 10 
psi (~20 ms) controlled by a Picospritzer III.  Capillary RBC velocity was captured with 
line scans (scan rate ~1 kHz) placed along the length of the capillary. RBC velocities (= 
Δx/Δt, mm/s) were calculated from parallel-to-flow line scan images using the contrast 
between FITC-dextran-labeled plasma and unlabeled RBCs, using a modified version of 
the LS-PIV algorithm in MATLAB described elsewhere [40].  
Parameter Estimation: A zero-phase running average filter (window size ~1 s) was used 
to smooth raw velocity data after outliers (raw data points > 3 standard deviations (SDs) 
from mean of trace) were removed. Onset of the evoked response was estimated by fitting 
a line to the slope between 20% and 80% to the peak of the response and calculating the 
time of the line’s x-intercept [58] (Figure 3-3). The 5-10 seconds immediately prior to 
puffing stimulation was considered baseline, and responses occurring within 20 seconds 
after the start of stimulation were analyzed. For the purpose of plotting pooled traces, data 
were interpolated at 10 ms intervals in order to line up the time axes. 
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3.3 Results and discusstion 
3.3.1 PO2-regulated RBC velocity in capillary is mediated by deoxyHb-band 
3 interaction. 
To explore the roles of deoxyHb-band 3 interaction in PO2-regulated RBC capillary 
velocity, we examined ex vivo RBC velocity in a microfluidic capillary using RBCs from 
three transgenic mice that contained “humanized” band 3 (Figure 3-4B) [21]. The first 
strain of mouse had RBCs that the NH2-terminal residues 1-45 on the cytoplasmic domain 
of band 3 was replaced by the homologous sequence (residues 1-35) of human band 3  
(mRBC-subst 1-35) [53], including the deoxyHb-band 3 binding site (residues 12-23). 
RBCs from the second strain of mouse had the same “humanized” band 3 except that the 
deoxyHb-band 3 binding site was deleted (mRBC-del 12-23). As a result, deoxyHb-band 
3 interaction was diminished or significantly weakened. RBCs from the third strain also 
had the same “humanized” band 3 but a homologous sequence (1-MEELQDDYEDM-11) 
Figure 3-3. Scheme showing the calculation of onset time of velocity increase in the in vivo puffing 
experiments. 
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adjacent to residues 12-23 of band 3 was removed (mRBC-del 1-11). Residues 1-11 are 
known to inhibit band 3 interaction with deoxyHb, removal of residues 1-11 thus enchances 
band 3-deoxyHb interaction [53]. RBCs from these three strains of mouse together with 
wild type mouse RBCs (mRBC-WT) were used to examine RBC velocity as a function of 
PO2 in microfluidics (Figure 3-4C). Particularly, RBCs were dispersed into a PBS buffer 
that was purged by N2 overnight. The RBC suspension was then injected at a constant 
pressure (1.6 psi) into a PDMS microfluidic device containing a constriction capillary (wc 
= 3 µm; h = 4 µm). The entire microfluidic device was immersed in a sulfite sink containing 
varied concentrations of sodium sulfite (an O2 scavenger) to control PO2 inside the 
microfluidic capillary. The motion of RBCs as a function of PO2 in the constriction was 
then recorded by a high speed camera (Figure 3-4D). The results showed that the velocity 
of mRBC-WT and mRBC-subst 1-35 increased linearly as the decrease of PO2 (Figure 3-
4E) (mRBC-WT: n = 146 cells, 3 subjects, 3 trials, RBC velocity [mm/s] = -0.132 × PO2 
[mmHg] + 26.455, R2 = 0.979; mRBC-subst 1-35: n =149 cells, 3 subjects, 3 trials, RBC 
velocity [mm/s] = -0.151 × PO2 [mmHg] + 28.913, R
2 = 0.995), consistent with previous 
findings in human RBCs. The sensitivity of RBC velocity to PO2 changes (slope of the 
fitting curve) was not signficantly different between mRBC-WT and mRBC-subst 1-35. 
The velocity of mRBC-subst 1-35, however, was significantly higher than that of mRBC-
WT at each PO2 level (Figure 3-3B). When RBCs with enhanced (mRBC-del 1-11) or 
weakened (mRBC-del 12-23) deoxyHb-band 3 interaction were used, the dependence of 
RBC velocity on PO2 was completely diminished (Figure 3-5A). In addition, the average 
velocity of mRBC-del 12-23 was signficantly lower than that of mRBC-del 1-11 (Figure 
3-5C), showing that reduced band 3-deoxyHb interaction could lead to decreased RBC 
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capillary velocity. These sets of data thus demonstrate that modification of deoxyHb-band 
3 interaction affects not only the magnitute of PO2-regulated RBC capillary velocity but 
also the sensitivity of RBC velocity to PO2 changes. 
 
We next examined whether deoxyHb-band 3 interaction also regulated RBC 
deformability. Figure 3-5D showed the microfluidic setup where a relatively wide 
constriction (wc = 10 µm, h = 7.4 µm) was used to mesure shear-induced elongation of 
RBCs. PO2 in the constriction was controlled by the sulfite sink and calibrated as described 
Figure 3-4. PO2-regulated RBC velocity in capillary is mediated by deoxyHb-band 3 interaction. 
(A) Scheme of the band 3-Hb interaction during deoxygenation. (B) Schematics of transgenic 
mRBCs with modified deoxyHb-band 3 interaction. (C) Setup for ex vivo analysis of PO2-regulated 
RBC velocity in capillary. (D) Time-lapse images showed that mRBCs flow faster at reduced PO2. 
Scale bar: 5 µm. 
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above. Shear-induced RBC elongation was characterized by using the elongation index, Dl 
/Dw, where Dl and Dw were, respectively, the length and thickness of an RBC flowing 
through the constriction. As shown in Figure 3-5E, elongation index of mRBC-WT and 
mRBC-subst 1-35 increased linearly as the decrease of PO2, indicating that RBC 
deformability increases at lower PO2 when deoxyHb-band 3 interaction is not compomised 
(mRBC-WT: n =209 cells, 3 subjects, 3 trials, Dl/Dw = -0.0228 × PO2 [mmHg] + 2.7548, 
R2 = 0.998; mRBC-subst 1-35: n = 195 cells, 3 subjects, 3 trials, Dl/Dw = -0.0137 × PO2 
[mmHg] + 2.6545, R2 = 0.994). 
 
Figure 3-5. Results showing PO2-regulated RBC velocity in capillary is mediated by deoxyHb-
band 3 interaction. (A) mRBC velocity in capillary as a function of PO2. (B) The velocity of mRBC-
WT is significantly lower than that of mRBC-subst 1-35. (C)  The velocity of mRBC-del 1-11 and 
mRBC-del 12-23 is not sensitive to surrounding PO2 changes. (D) A schematic of the setup for ex 
vivo analysis of RBC deformability. (E) The elongation index (Dl/Dw) of mRBC increased linearly 
as the decrease of PO2. (F) The Dl/Dw of mRBC and was not sensitive to PO2 changes and remains 
relatively constant. 
A B C 
F 
E D 
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When RBCs with modified deoxyHb-band 3 interaction were used (mRBC-del 12-23 and 
mRBC-del 1-11), the elongation index of these RBCs was not dependent on PO2 and the 
average elongation index of mRBC-del 12-23 was signficantly smaller than that of mRBC-
del 1-11 (Figure 3-5B). These data of PO2-regulated RBC deformability as a function of 
deoxyHb-band 3 interaction are consistent with the results of PO2-regulated RBC capillary 
velocity and suggest that RBC deformability correlate tightly to RBC capillary velocity.  
 
3.3.2 Transgenic mice with modified deoxyHb-band 3 interaction exhibit 
PO2-independent capillary hyperemia in vivo 
Although ex vivo microfluidic experiments demonstrated that the dependence of 
RBC capillary velocity on PO2 could be manipulated by altering RBC band 3-deoxyHb 
interactions, it remained unclear whether band 3-deoxyHb interaction also contributed to 
PO2-regulated RBC capillary velocity in vivo. To address this question, we used a laser 
scan two-photon microscope to measure in vivo RBC capillary velocity as a function of 
tissue PO2 in the cerebral cortex of wild type mice (mRBC-WT) and transgenic mice 
(mRBC-subst 1-35, mRBC-del 1-11, and mRBC-del 12-23). 
Under the guidance of two-photon imaging, we microinjected a sodium sulfite 
solution to the hindlimb cortex of a mouse brain to control local tissue PO2 near capillaries  
(Figure 3-6A). Microinjection of sulfite triggered a rapid decrease in local tissue PO2 and 
such PO2 dips increased as the increase of sulfite concentration (Figure 3-6B). 
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             Note that the bi-phasic pattern of PO2 response to sulfite puffing, e.g., an initial 
transient dip followed by a delayed long-lasting overshoot, was similar to previously 
Figure 3-6. Transgenic mice with modified deoxyHb-band 3 interaction exhibit PO2-independent 
capillary hyperemia in vivo. (A) Setup for in vivo assessing cererbal capillary hyperemia and tissue 
PO2 upon locally applied O2 scavenger in the mouse cerebral cortex. Scale bar: 30 µm. (B) Local 
changes of PO2 are dose-dependent on the concentration of microinjected sulfite. (C) Typical 
images of the two-photon linescan of a capillary before and afer the microinjection of sulfite. (D) 
Time-course plot of RBC capillary velocity increase after microinjection of sulfite for mRBC-WT 
and transgenic mice (E) subst 1-35, (F) del 1-11, and (G) del 12-23. (H) The onset time of increase 
of RBC capillary velocity after sulfite puffing. 
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observed activity-dependent PO2 responses [30]. We then measured RBC velocity in 
capillaries as a function of local tissue PO2 changes using a two-photon linescan.  A typical 
linescan image acquired in mRBC-WT with longitudinal linescan before and after sulfite 
puffing was shown in Figure 3-6C, where x represents the scanning distance and t is time. 
Each RBC in the linescan image appeared as a black stripe and the slope of the stripe was 
velocity, v. Upon sulfite puffing, RBC capillary velocity increased. In mRBC-WT and 
mRBC-subst 1-35 mice, the peak velocity and the increase of peak velocity relative to 
baseline induced by 1M sulfite puffing were significantly higher than that by 0.01M sulfite 
puffing (Figure 3-6D and 3-6E), showing that in vivo RBC capillary velocity is regulated 
by local PO2 changes. In mRBC-del 1-11 mice (Figure 3-6F) and mRBC-del 12-33 mice 
(Figure 3-6G) where band 3-deoxyHb interaction was respectively enhanced and 
weakened, however, the peak velocity and increase of peak velocity after sulfite puffing 
did not change as the increase of sulfite concentration, suggesting that local PO2 changes 
fail to regulate RBC capillary velocity. These in vivo results are consistent with our ex vivo 
findings and highlight again the regulatory roles of deoxyHb-band 3 interaction in PO2-
dependent RBC capillary velocity. In addition, we further noticed that, upon sulfite puffing, 
the onset time of RBC velocity increase was significantly shorter in mRBC-subst 1-35 mice 
comparing to  mRBC-WT mice (Figure 3-6H), suggesting that mouse RBCs with 
“huamnized” band 3 have a faster response time to PO2 changes than WT mouse RBCs. 
The onset time of RBC velocity increase in mRBC-del 12-33 and mRBC-del 1-11 mice 
was respectively longer and comparable to that in mRBC-WT mice. 
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3.3.3 Biochemical modulation of deoxyHb-band 3 interaction in wild type 
RBCs regulates PO2-dependent RBC velocity in capillary 
To further evaluate the roles of deoxyHb- band 3 interaction in PO2-regulated RBC 
capillary velocity, we utilized phosphoenolpyruvic acid (PEP), sodium phosphate (Pi) and 
pervanadate treatments to manipulate deoxyHb-band 3/band 3-cytoskeleton interactions in  
wild type mouse RBCs and human RBCs (Figure 3-7A). RBCs treated with PEP and Pi 
have increased and decreased intracellular concentration of 2,3-diphosphoglyceric acid 
(2,3-DPG), respectively. Because 2,3-DPG binds preferably to deoxyHb [59, 60], increase 
of 2,3-DPG, e.g., via PEP treatment, reduces the amount of deoxyHb available to bind band 
3.  In contrast, decrease of 2,3-DPG via Pi treatment increases the amount of deoxyHb 
available to bind band 3 [61]. 
Such change of the amount of deoxyHb is expected to alter the quantity of 
deoxyHb-band 3 association and its assoicated kinetic process, and consequently affects 
the magnitude of RBC capillary velocity and its sensitivity to PO2 changes. Indeed, when 
both human RBCs and wild type mouse RBCs were treated with PEP and Pi and tested as 
a function of PO2 in a microfluidic capillary, the sensitivity of RBC velocity to PO2 changes 
(slope of the fitting curve) was significantly reduced after PEP and Pi treatments (Figure 
3-7B and 3-7C). Velocity of hRBC-WT decreased linearly with the increase of PO2 
(hRBC-WT: n= 71 RBCs, 3 subjects, 3 trials, RBC velocity [mm/s] = -0.451× PO2 [mmHg] 
+ 82.074, R2 = 0.999). After pervanadate treatment (hRBC-Pervanadate), RBC velocity 
was not sensitive to PO2 changes and remained constant at 79.56 ± 0.28 mm/s (n = 198 
RBCs, 4 subjects, 4 trials). RBC treated with Pi solution (hRBC-Pi) flew faster than that 
treated with PEP solution (hRBC-PEP). 
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The sensitivity of RBC velocity to PO2 changes (as indicated by the slope) was 
reduced for both cases (hRBC-Pi: n= 174 RBCs, 4 subjects, 4 trials, RBC velocity [mm/s] 
= -0.068× PO2 [mmHg] + 79.332, R
2 = 0.947; hRBC-PEP: n= 167 RBCs, 4 subjects, 4 
trials, RBC velocity [mm/s] = -0.065× PO2 [mmHg] + 74.198, R
2 = 0.906). The elongation 
index of hRBC-WT decreased linearly with the increase of PO2 (hRBC-WT: n =239 RBCs, 
3 subjects, 3 trials, Dl/Dw = -0.0236 × PO2 [mmHg] + 4.0001, R
2 = 0.934). After 
pervanadate treatment (hRBC-Pervanadate), RBC deformation was not sensitive to PO2 
changes and remained constant at 4.08 ± 0.02 mm/s (n = 216 RBCs, 3 subjects, 3 trials).  
RBC treated with Pi solution (hRBC-Pi) was more deformation than that treated with PEP 
solution (hRBC-PEP). RBC deformation was less sensitivity to PO2 changes for both cases 
(hRBC-PEP: n=144 RBCs, 3 subjects, 3 trials, Dl/Dw = -0.0102 × PO2 [mmHg] + 3.6698, 
R2 = 0.997; hRBC-Pi: n= 132 RBCs, 3 subjects, 3 trials, Dl/Dw = -0.0143 × PO2 [mmHg] 
+ 4.142, R2 = 0.947). In addition, the velocity of RBCs treated with PEP was significantly 
lower than that of RBCs treated with Pi at each PO2 level. 
Furthermore, when RBCs were treated with pervanadate, which directly triggers 
tyrosine phosphorylation of band 3 and induces the disassociation of band 3 from its 
ankyrin linkage to the spectrin-actin skeleton without PO2-dependent deoxyHb-band 3 
interaction [62, 63], the dependence of RBC velocity on PO2 was completely diminished 
(Figure 3-7B and 3-7C). The velocity of RBCs treated with pervanadate was also 
significantly higher than that of RBCs treated with PEP at most PO2 levels. When RBC 
deformability (in terms of elongation index) as a function of PO2 was further examined 
after PEP, Pi and pervanadate treatments, the sensitivity of RBC deformation to PO2 
changes was significantly reduced after PEP and Pi treatments and diminished after 
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pervanadate treatment (Figure 3-7D and 3-7E). The dependence of RBC velocity on PO2 
for wild type mRBC (mRBC-WT) (mRBC-WT: n = 146 RBCs, 3 subjects, 3 trials, RBC 
velocity [mm/s] = -0.132 × PO2 [mmHg] + 26.455, R
2 = 0.979) was diminished after 
pervanadate treatment (mRBC-Pervanadate, velocity is constant at 23.74 ± 0.13 mm/s, n = 
138 RBCs, 3 subjects, 3 trials). The sensitivity of RBC capillary velocity to PO2 changes 
was reduced after Pi and PEP treatments (mRBC-PEP: n = 146 RBCs, 3 subjects, 3 trials, 
RBC velocity [mm/s] = -0.071 × PO2 [mmHg] + 22.557, R
2 = 0.885; mRBC-Pi: n = 159 
RBCs, 3 subjects, 3 trials, RBC velocity [mm/s] = -0.11 × PO2 [mmHg] + 28.296, R
2 = 
0.938). The dependence of RBC defomration on PO2 in mRBC-WT (mRBC-WT: n = 207, 
Dl/Dw = -0.0228 × PO2 [mmHg] + 2.7548, R
2 = 0.998) was diminished after pervanadate 
treatment (Dl/Dw is constant at 2.44 ± 0.03, n= 216 RBCs, 3 subjects, 3 trials). 
The sensitivity of RBC deformation to PO2 changes was also reduced after Pi and 
PEP treatments (mRBC-PEP: n = 120 RBCs, 3 subjects, 3 trials, Dl/Dw = -0.0107 × PO2 
[mmHg] + 2.4383, R2 = 0.989; mRBC-Pi:  n = 125 RBCs, 3 subjects, 3 trials, Dl/Dw = -
0.005 × PO2 [mmHg] + 2.8088, R
2 = 0.988). The magnitude of elongation index at each 
PO2 level was lower for RBCs treated PEP comparing with RBCs treated with Pi and 
pervanadate. Such similar trend of RBC deformability as a function of PO2 as the observed 
PO2-regulated RBC capillary velocity in wild type mouse RBCs and human RBCs 
highlights again the tight correlation between RBC deformability and RBC capillary 
velocity. Importantly, the data further suggests that PO2-dependent RBC deformability and 
capillary velocity can be manipulated by controlling intracellular 2,3-DPG concentration 
and band 3 phosphorylation, which in turn regulates deoxyHb-band 3 and band 3-
cytoskeletal interactions. 
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Figure 3-7. Biochemical modulation of band 3-deoxyHb interaction regulates PO2-dependent RBC 
velocity in capillary. (A) Schematics of the biochemical approaches used to modulate band 3-
deoxyHb and band 3-cytoskeletal interactions. Left: Band 3-deoxyHb interaction is manipulated 
by increasing or decreasing intracellular concentration of 2,3-DPG, which competes the deoxyHb 
binding site in band 3. Right: Tyrosine phosphorylation of band 3 (via pervanadate treatment) 
promotes dissociation of band 3 from the spectrin-actin skeleton. (B) Velocity of human RBCs in 
a microfluidic capillary (wc = 5 µm, h = 7 µm) as a function of PO2. (C) Deformation of human 
RBCs measured by the elongation index (Dl/Dw) in a microfluidic constriction (wc = 20 µm, lc = 
100 µm, h = 30 µm) as a function of PO2. (D) Velocity of murine RBCs in a microfluidic capillary 
(wc = 3 µm, h = 4.5 µm) as a function of PO2. (E) Deformation of murine RBCs measured by the 
elongation index (Dl/Dw ) in a microfluidic constriction (wc = 10 µm, lc = 100 µm,  h = 7.35 µm) as 
a function of PO2.  
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3.3.4 Dynamics of PO2-regulated RBC velocity in capillary 
Although the results from both ex vivo and in vivo experiments have shown that 
deoxyHb-band 3 and band 3-cytoskeletal interactions contribute to PO2-regulated RBC 
capillary velocity and deformability, the underlying mechanisms are elusive and several 
fundamental questions remain. For example, what is the evidence of RBC membrane 
detachment during deoxygenation? Does the duration of reduced PO2 matter? How 
quantitatively does RBC capillary velocity relate to its deformability and why do RBCs 
with a higher deformability flow faster in capillary? 
To answer these questions, we first examined the RBC membrane detachment 
during deoxygenation by measuring the change of RBC tank-treading frequency as a 
function of PO2. Tank-treading motion of a RBC, which normally occurs in a shear flow, 
refers to the rotation of the RBC membrane around the cell body. The frequency of such 
motion is mainly determined by the applied shear rate, viscosity of the suspending solution, 
and the membrane-cytoskeletal interaction. Therefore, at a constant shear rate and medium 
vicosity, RBCs with disrupted membrane-cytoskeletal interactions are expected to have an 
increased tank-treading frequency. Figure 3-8A showed the microfluidic setup where a 
microfluidic channel with a constriction (wc = 20 µm and h = 38 µm) was used to induce 
RBC tank-treading motion in flow. Human RBCs attached with microspheres (1 µm, 
polystyrene) were injected to the microfluidic channel and the tank-treading frequency (f 
(s-1)), which is the inverse of the orbital period (the time for the microbead moving along 
with the RBC membrane for one revolution), was measured using a high-speed camera. In 
addition, we varied the length of the channel prior to constriction to achieve the exposure 
time of reduced PO2, ttotal, at 18 ± 4 ms, 192 ± 30 ms and 377 ± 11 ms, respectively. PO2 
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inside the channel was calibrated as described previously. As shown in Figure 3-8B, the 
normalized tank-treading frequency, f (s-1) / f (s-1)34 mmHg, where f (s
-1)34 mmHg is the tank-
treading frequency at PO2 = 34 mmHg, was independent on PO2 changes when ttotal was 18 
± 4 ms. However, when ttotal was increased to 192 ± 30 ms and 377 ± 11 ms,  f (s
-1) / f (s-
1)34 mmHg increased linearly with the decrease of PO2. When ttotal = 192 ± 30 ms, tank 
treading frequency changed linearly with PO2 and was more sensitivity to PO2 changes 
when the viscosity was higher (Table 3-2).(η = 1.36 mPa·s: n = 80 RBCs, 3 subjects, 3 
trials,  f / f 34mmHg = -0.0043 × PO2 (mmHg) + 1.1326, R
2 = 0.839; η = 2.61 mPa·s: n = 116 
RBCs, 3 subjects, 3 trials, f / f 34mmHg = -0.0062 × PO2 (mmHg) + 1.2036, R
2 = 0.959; η = 
4.66 mPa·s: n = 120 RBCs, 3 subjects, 3 trials,  f / f 34mmHg = -0.0115 × PO2 (mmHg) + 
1.3509, R2 = 0.874). The same trend was applied when ttotal was increased to 377 ± 11 ms 
(η = 1.36 mPa·s: n = 129 RBCs, 3 subjects, 3 trials, f / f 34mmHg = -0.0072 × PO2 (mmHg) + 
1.2253, R2 = 0.894; η = 2.61 mPa·s: n = 160 RBCs, 3 subjects, 3 trials, f / f 34mmHg = -0.0117 
× PO2 (mmHg) + 1.3677, R
2 = 0.920; η = 4.66 mPa·s: n = 120 RBCs, 3 subjects, 3 trials,  
f / f 34mmHg = -0.0141 × PO2 (mmHg) + 1.4461, R
2 = 0.924).  
 
Table 3-2. Dimensions of microfluidic channels in use for human RBC measurement 
Exposure time Viscosity Fitting correlations 
ttotal = 192 ± 30 ms 1.36 mPa·s f / f 34mmHg = -0.0043 × PO2 (mmHg) + 1.1326 
ttotal = 192 ± 30 ms 2.61 mPa·s f / f 34mmHg = -0.0062 × PO2 (mmHg) + 1.2036 
ttotal = 192 ± 30 ms 4.66 mPa·s f / f 34mmHg = -0.0115 × PO2 (mmHg) + 1.3509 
 
Exposure time Viscosity Fitting correlations 
ttotal = 377 ± 11 ms 1.36 mPa·s f / f 34mmHg = -0.0072 × PO2 (mmHg) + 1.2253 
ttotal = 377 ± 11 ms 2.61 mPa·s f / f 34mmHg = -0.0117 × PO2 (mmHg) + 1.3677 
ttotal = 377 ± 11 ms 4.66 mPa·s f / f 34mmHg = -0.0141 × PO2 (mmHg) + 1.4461 
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The sensitivity of the tank-treading frequency to PO2 changes was also increased 
as the increase of ttotal and medium viscosity (Figure 3-8C), strongly suggesting the 
disrupted membrane-cytoskeletal interaction during sustained deoxygnation. Furthermore, 
at each PO2 levels, RBC tank-treading frequency increased as the increase of the viscosity 
of the RBC susepension, consistent with previous literature findings [16]. The results 
demonstrate a PO2-regulated RBC tank-treading motion that depends on both the exposure 
time of reduced PO2 and medium viscosity and thus support evidently the disrupted RBC 
membrane-cytoskeletal interaction during deoxygenation. 
To further test whether PO2-regulated RBC capillary velocity is also affected by 
the duration of reduced PO2, we measured RBC capillary velocity using another series of 
microfluidic capillaries with controlled ttotal. The results as shown in Figure 3-8D 
demonstrated that the normalized RBC velocity, v0mmHg/v34 mmHg where v0mmHg and v34 mmHg 
were the RBC velocity at PO2 = 0 mmHg and PO2 = 34 mmHg, respectively, was 
independent on ttotal for transgenic mice with modified band 3-deoxyHb interaction 
(mRBC-del 1-11 and mRBC-del 12-23). In contrast, the normalized RBC velocity of 
human RBCs (hRBC-WT), transgenic mouse RBCs with “humanized” band 3 (mRBC-
subst 1-35), and wild type mouse RBCs (mRBC-WT) increased with the increase of ttotal 
and reached a maximum when ttotal was about 351.3 ± 25 ms, 913.4 ± 63 ms and 955.1 ± 
57 ms, respectively. Beyond such threshold of ttotal, RBC capillary velocity became 
independent of PO2 changes. These data thus show that not only does the ttotal affect PO2-
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regulated RBC capillary velocity and but also the existence of a critical ttotal beyond which 
RBC capillary velocity is independent on PO2 changes. Furthermore, the smaller critical 
ttotal of human RBCs and mouse RBCs with humanized band 3 (mRBC-subst 1-35) 
comparing to that of wild type mouse RBCs implies a fast response time of human RBCs 
to PO2 changes, which is further evidenced by the shortest in vivo onset time of RBC 
capillary velocity increase in mRBC-subst 1-35 (Figure 3-6H). 
 
Figure 3-8. Dynamics of PO2-regulated RBC velocity in capillary. (A) Schematics of experimental 
setup for ex vivo analysis of RBC tank treading frequency at reduced PO2. (B) Effect of total 
exposure time of reduced PO2 (ttotal) on tank treading frequency of human RBCs, f (s-1). Dextran 
was added to increase the viscosity of RBC suspension (1.36 mPa·s, 2.61 mPa·s, and 4.66 mPa·s). 
(C) Magnitude of slope comparison under different viscosities. (D) Effect of total exposure time of 
reduced PO2 (ttotal) on RBC velocity in microfluidic capillary. (E) Schematics of the relation 
between PO2, RBC deformability, and capillary velocity. RBCs are more deformable at reduced 
PO2 and thus have a smaller cell width (2r0) when flowing in a capillary with a diameter of 2R0. As 
a result, the gap distance between the surface of RBC and the capillary wall (R0-r0) increases, 
leading to a high RBC velocity. (F) Experimental measured changes of RBC width r0 and RBC 
velocity v as a function of PO2.  
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Last, we evaluate the correlation between RBC capillary velocity and RBC 
deformability by analyzing the changes of the RBC width r0 in capillary as a function of 
PO2 (Figure 3-8E). According to the classical Bretherton scaling for a long bubble flowing 
in a microchannel, the normalized gap distance between the channel wall and the surface 
of the bubble, (𝑅0 − 𝑟0 𝑏𝑢𝑏𝑏𝑙𝑒) 𝑅0⁄  where 𝑅0 and 𝑟0 𝑏𝑢𝑏𝑏𝑙𝑒 is the radius of the channel and 
the bubble respectively, is  proportional to 𝐶𝑎
2
3⁄  where 𝐶𝑎 =
𝜇𝑣
𝜎
 is the capillary number, 
µ is viscosity, v is velocity and σ is surface tension. In the case of RBCs, if we assume the 
membrane tension E on RBCs is uniform, Ca can be expressed as 𝐶𝑎 =
𝜇𝑣
𝐸
. Thus, a more 
deformable RBC membrane with a small E, e.g., at reduced PO2, will lead to a large Ca, 
and consequently an increased gap distance. Given the channel radius 𝑅0  is constant, 
increased gap distance implies a decreased RBC width r0 in the channel. Indeed, when we 
measured the change of cell width as a function of PO2, the normalized cell width, r0 / r0 
34mmHg, where r0 34mmHg is the cell width at PO2 = 34 mmHg decreased as the decrease of 
PO2 (Figure 3-8F), supporting the proposed Bretherton model. Furthermore, such increase 
of gap distance due to increased RBC deformability would reduce the shear stress acting 
on RBCs and consequently result in an increased RBC capillary velocity at a constant 
pressur drop. We calculated the shear stress using lubrication approximation and showed 
that the non-dimensional form of RBC capillary velocity can be written as 
𝑣0̅̅ ̅ = 𝑣0
𝜇
𝑅0
2 (−
𝑑𝑝
𝑑𝑥
)−1 = (
𝑟0
𝑅0
)2𝑙𝑛
𝑅0
𝑟0
−
1
4
[1 − (
𝑟0
𝑅0
)
2
], 
which only depends on the ratio of r0/R0. Therefore, it is likely that, with the decrease of 
PO2,  RBCs become more deformabile due to the deoxyHb-band 3 and band 3-cytoskeletal 
interactions, resulting in a decreaed cell width inside the capillary, which in turn increases 
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the gap distance between the cell and the channel wall and consequently inceases its 
capillary velocity.  
 
3.3.5 Discussion 
Recent studies have revealed that functional hyperemia is initiated in capillary [64, 
65] and RBCs themselves can act as oxygen-sensing regulators to control capillary RBC 
velocity in response to local PO2 changes.  However, the underlying mechanisms of how 
PO2 could modulate RBC velocity in capillary are not clear. Experimental findings 
presented here implied that deoxyHb-band 3 interaction in RBCs is the molecular switch 
that responds to local PO2 changes and controls RBC deformability and consequently RBC 
capillary velocity. DeoxyHb-band 3 interaction occurs at reduced PO2 and causes a 
transient rupture of the band 3-ankyrin bridge between the RBC membrane and 
spectrin/actin cytoskeleton, resulting in weakened membrane-cytoskeletal interactions 
during deoxygenation [21, 51-53]. Such compromised interactions are expected to lead to 
increased RBC deformability and capillary velocity. Evidently, we showed that 1) while 
ex vivo capillary velocity and deformation of RBCs from WT mice exhibited a linear 
relation with local PO2 changes, RBCs from transgenic mice that had enhanced or 
weakened deoxyHb-band 3 interaction showed PO2-independennt changes of capillary 
velocity and deformation. RBCs with enhanced deoxyHb-band 3 interaction showed higher 
capillary velocity and deformability comparing to RBCs that had weakened deoxyHb-band 
3 interaction. 2) Consistent with ex vivo results, in vivo cerebral capillary hyperemia in WT 
mice but not transgenic mice that had RBCs with enhanced or weakened deoxyHb-band 3 
interaction was dependent on local PO2 changes. 3) RBCs from WT mice and human 
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treated biochemically to modify the deoxyHb-band 3 and band 3-ankyrin interactions 
showed corresponding PO2-regulated capillary velocity and deformation. 4) RBC 
membrane tank-treading frequency increased linearly with the decrease of PO2 and the 
longer the PO2 exposure time, the higher the tank-treading frequency was, highlighting the 
occurrence of membrane-cytoskeletal detachment during deoxygenation. Collectively, 
these sets of data indicate that, in response to local PO2 changes, RBCs can modulate 
membrane-cytoskeletal interactions via deoxyHb-band 3 association, and consequently 
control RBC deformability and capillary velocity. 
It is important to note that there is a significant amount of Hb (~ 270, 000, 000 
copies) but a limited number of band 3 (~1,200,000 copies) per RBC. As a result, only ~ 
0.4% Hb will be available to bind band 3 during deoxygenation and thus deoxyHb-band 3 
interaction will unlikely affect the O2 delivery in RBCs. Furthermore, because 
deoxygenation starts to occur near the cell membrane when PO2 decreases, Hbs that are in 
close proximity to the cell membrane will be deoxygenated first and bind band 3. 
Considering a simplified one-step binding reaction between of deoxyHb and band 3, the 
equilibrium binding constant, Ke, is determined by the ratio of the on-rate constant kon and 
the off-rate constant koff, 𝐾𝑒 =
𝑘𝑜𝑛
𝑘𝑜𝑓𝑓
⁄ . In the case of mRBC-del 1-11 where deoxyHb-band 
3 interaction is enhanced by deleting the inhibitory residues 1-11 on band 3, Ke increases 
due to the decrease of koff. In contrast, Ke decreases due to the decrease of kon in mRBC-del 
12-23 where deoxyHb-band 3 interaction is weakened by deleting the deoxyHb binding 
site (residues 12-23) on band 3. Because deoxyHb sterically displaces ankyrin upon 
binding to band 3, the stronger the deoxyHb-band 3 interaction is (e.g., larger Ke), the more 
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likely the band 3-ankryin bridge is disrupted, and consequently RBCs become more 
deformable. 
In addition, we note that RBC deformability and capillary velocity are independent 
of PO2 when deoxyHb-band 3 interaction is either weakened by deleting the deoxyHb 
binding residues 12-23 or enchanced by deleting the inhibitory residues 1-11 on band 3. It 
is understandable that RBC’s deformability and capillary velocity do not respond to PO2 
changes when the deoxyHb binding site on band 3 is deleted, but why there are no PO2-
dependent responses even when the deoxyHb-band 3 interaction is enhanced? As discussed 
previously, the amount of deoxyHb that binds to band 3 only counts ~0.4% of the entire 
intracellular Hb and most of them likely come from Hbs that are close to the cell membrane 
during deoxygenation. Thus, such a small amount of Hb will require tiny decrease of PO2 
to become deoxygenated and then bind to band 3. In the case of WT RBCs, the binding 
rate at this early stage is slow due to the presence of the inhibitory residues 1-11 on band 
3. With the further decrease of PO2, more and more deoxyHb are available and the binding 
rate increases accordingly, exhibiting a PO2 dependent deoxyHb-band 3 interaction and 
thus the observed PO2-regulated RBC deformability and capillary velocity. In the case of 
enhanced deoxyHb-band 3 interaction where the inhibitory residues 1-11 on band 3 are 
deleted, however, the deoxyHb-band 3 binding at the initial stage of deoxygenation is fast 
and strong and deoxyHb produced from further PO2 decrease do not contribute to the 
binding process anymore, and thus present PO2-independet RBC responses.  RBCs treated 
with PEP with decreased amount of deoxyHb available to bind band 3 highlight again the 
decreased rate constant (kinetics) such that the sensitivity to PO2 changes decreases. 
Similarly, when such regulation was reduced in Pi treated RBCs, deoxyHb near the cell 
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mebrane can bind band 3 readly duing deoxygnation and thus also decrease the sensitivity 
to PO2 changes. 
Indeed, the fact that there is a critical RBC response time in WT RBCs beyond 
which RBC capillary velocity do not depend on PO2 anymore further highlights the 
discussed kinetic process: when the deoxygenation process is close to complete (~400 ms), 
the deoxyHb-band 3 interaction reaches an equilibrium and thus RBC capillary velocity 
does not change with PO2.  Note that the 1s of RBC response time to PO2 changes is close 
to RBC capillary transit time in the brain, further emphasizing the regulatory roles of RBC 
in control its velocity in capillary. In addition, human RBCs have the shortest response 
time to PO2 changes, followed by RBCs from transgenic mice with humanized band 3 
(mRBC-subst 1-35), and then WT mouse RBC, suggesting species-specific deoxyHb-band 
3 interaction. Lastly, it should be noted that volume changes of RBCs will affect the 
measured RBC velocity and thus RBC volume was assumed to be constant during the 
capillary velocity measurement. However, it is known that PO2 can also regulate cation 
flux in RBCs and thus controls RBC volume. In addition, the mechanosensing ion channels 
on RBCs, Piezo1 will be activated due to the significant deformation in capillary and plays 
a role in regulating ion flux and cell volume. Thus, it is likely that deoxyHb-band 3 
interaction mediated RBC capillary velocity contributes partially to the observed PO2-
regulated RBC capillary velocity and other factors that regulate RBC volume also exist. 
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3.4 Conclusion 
In summary, we demonstrate that RBCs are the active players in regulating 
capillary hyperemia by controlling the band 3-deoxygen interaction/band 3-ankyrin 
interaction at different PO2 levels. Such red cell properties change at different PO2 levels 
leads to red cell deformation and capillary velocity change, which facilitate capillary 
hyperemia. The results suggest a novel yet effect approach to manipulate functional 
hyperemia by controlling red cell properties, without the input from neuron, astrocyte or 
the unit. A possible therapeutic approach to treat neurodegenerative disease, stroke, etc. 
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4. PIEZO1 REGULATES MECHANO-TRANSDUCTIVE 
RELEASE OF ATP FROM HUMAN RBCS 
Piezo proteins (Piezo1 and Piezo2) are recently identified mechanically activated cation 
channels in eukaryotic cells and associated with physiological responses to touch, pressure, 
and stretch. In particular, human RBCs express Piezo1 on their membranes, and mutations 
of Piezo1 have been linked to hereditary xerocytosis. However, physiological functions of 
Piezo1 on normal RBCs remain poorly understood. Here, we show that Piezo1 regulates 
mechanotransductive release of ATP from human RBCs by controlling the shear-induced 
calcium (Ca2+) influx. We find that, in human RBCs treated with Piezo1 inhibitors or 
having mutant Piezo1 channels, the amounts of shear-induced ATP release and Ca2+ influx 
decrease significantly. Remarkably, a critical extracellular Ca2+ concentration is required 
to trigger significant ATP release, but membrane-associated ATP pools in RBCs also 
contribute to the release of ATP. Our results show how Piezo1 channels are likely to 
function in normal RBCs and suggest a previously unidentified mechanotransductive 
pathway in ATP release. Thus, we anticipate that the study will impact broadly on the 
research of red cells, cellular mechanosensing, and clinical studies related to red cell 
disorders and vascular disease. 
  
61 
 
4.1 Introduction 
Mechanical stress-induced deformation of human RBCs plays important 
pathophysiological roles in oxygen delivery, blood rheology, transfusion, and malaria [66-
69]. Recent studies show that, in response to shear-induced stretch, RBCs release ATP [17, 
70-73], suggesting the existence of mechanotransductive pathways in RBCs. Most 
importantly, RBCs participate in vascular signaling through the mechanotransductive 
release of ATP and contribute to the control of microvascular tone [22, 23]. The released 
ATP from RBCs, for example, binds and activates the purinergic G coupled protein 
receptors (P2Y receptors) on vascular endothelial cells and induces the synthesis and release 
of nitric oxide [74, 75], a well-known vasodilator as illustrated in Figure 4-1 [91]. 
Moreover, impaired release of ATP from RBCs has been linked to diseases, such as type 
II diabetes and cystic fibrosis [76, 77]. Given that RBCs experience shear stresses 
continuously during the circulation cycle and that the released ATP plays a central role in 
vascular pathophysiology, understanding of the mechanotransductive release of ATP from 
RBCs will provide not only fundamental insights to the roles of RBCs in vascular 
homeostasis but also, potential therapeutic strategies for red cell dysfunction and vascular 
disease. 
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Previous studies have shown that the addition of chemicals that stiffen RBC 
membranes decreases the amount of ATP released [17, 78], indicating that deformation of 
the cell membrane is a necessary trigger. In addition, biological mediators, such as cystic 
fibrosis transmembrane conductance regulator (CFTR) and pannexin-1 hemichannels, are 
involved in the release pathways of mechanotransductive ATP release from RBCs [17, 76, 
79, 80]. Inhibition of CFTR leads to an impaired ATP release from deformed RBCs [76]. 
Recent studies, including our previous findings, suggest that interactions between 
membrane-associated actin and CFTR play important roles in the mechanotransductive 
ATP release from RBCs [17, 79]. Pannexin-1, however, is a channel-forming protein and 
Figure 4-1. Illustration showing the entrance of RBCs into tissues. RBCs provide oxygen supply 
as well as ATP. As long as P2Y receptors bind with ATP, vasodilation occurs. [91] 
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has been suggested as a mechanosensing ATP release channel [80]. Under osmotic stress, 
for example, ATP released from RBCs was attenuated by carbenoxolone, a highly effective 
pannexin channel blocker, suggesting that pannexin-1 might be one of the conductance 
channels responsible for the mechanotransductive release of ATP (Figure 4-2) [80]. 
Although progress has been made in understanding mechanotransductive ATP release from 
RBCs, many questions remain about the signal transduction pathways. For example, how 
does mechanical force transduce signals to ATP release channels? Are there any stretch-
activated ion channels on RBCs that may sense mechanical forces and activate ATP 
release? If so, are there any secondary messengers that could be generated by mechanical 
stimuli and regulate ATP release? 
 
Piezo proteins (Piezo1 and Pizeo2) are recently identified mechanically activated 
cation channels in mammals [58, 81] and can be fully activated without involvement of 
additional proteins [81, 82]. Piezo-induced cationic currents were first observed in the 
Neuro2A mouse cell line, but subsequent studies have shown that Piezo proteins are able 
Figure 4-2. Scheme depicting a possible path way of blood flow regulation through pannexin 1 
channels. [80] 
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to mediate mechanically activated cationic currents in a variety of cell types, including 
endothelial cells [83, 84] and neuronal stem cells [85]. In particular, mature RBCs and 
erythroid progenitor cells express Piezo1 on their membranes [86], and mutations in the 
Piezo1 channels on mature RBCs are associated with hereditary xerocytosis (HX) [87, 88], 
a disease that is characterized by RBC dehydration and hemolytic anemia. To date, 
however, the physiological roles of Piezo1 in healthy RBCs remain poorly understood [88], 
and whether Piezo1 participates in the mechanotransductive release of ATP from RBCs is 
completely unknown. We hypothesize that Piezo1 controls shear-induced Ca2+ influx in 
RBCs and participates in the regulation of mechanotransductive release of ATP from 
RBCs. To test the hypothesis, we have implemented a microfluidic approach to control the 
shear-induced deformation of RBCs in flow and identify the regulatory roles of Piezo1 in 
shear-induced ATP release and Ca2+ influx in RBCs. Additionally, we show the correlation 
between stretch-evoked Ca2+ influx and ATP release from RBCs and reveal a threshold 
concentration of extracellular Ca2+ necessary for triggering shear-induced ATP release. 
Lastly, functional roles of membraneassociated ATP pools and potential ATP release 
channels in the shear-induced ATP release are investigated, and a model of 
mechanotransductive ATP release from RBCs is proposed. 
 
4.2 Experimental methods 
4.2.1 Microfluidic fabrication and experimental setup 
Microfluidic devices were fabricated out of PDMS (Slygard 184) using the standard 
soft lithography technique. Three-inch silicon wafers (University Wafers) were patterned 
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using epoxy-based negative photoresist (SU-8) (Microchem) photoresist, and then, PDMS 
(10:1 curing ratio) was cast on the wafer molds. For each experiment, 1.0 mL 10% (vol/vol) 
RBCs suspension was loaded into a syringe (Hamilton), which is connected to a 
polyethylene (PE 20) tube by a syringe needle (27 gauge). The other end of the tube was 
inserted into the inlet of microfluidic devices. The syringe was placed onto a syringe pump 
(Harvard Apparatus Phd Ultra; Harvard Apparatus), and suspension was flowed at a rate 
of 3.0 μl/min. 
 
4.2.2 RBC preparation 
Human RBCs were drawn from healthy donors and used on the same day of 
experiments. To treat RBCs with Piezo1 inhibitors, 10% (vol/vol) RBCs were incubated 
with 10 μM GsMTx4 (Peptides International, Inc.), 30 μM Gd3+ (Sigma), or ruthenium red 
(Sigma) in physiological salt solution (PSS) at 37 °C for 30 min. To inhibit CFTR and/or 
pannexin-1 channels on RBCs, 10% (vol/vol) RBCs were incubated with 50 μM 
glibenclamide and/or carbenoxolone at 37 °C for 30 min. Glibenclamide (Sigma) was 
prepared by following the protocol in ref. [76] and diluted from a 10 mM stock solution to 
50 μM in PSS. Carbenoxolone was diluted from 1.0 mM stock solution to 50 μM in PSS. 
All treated cells were washed with a PBS solution three times and resuspended into the 
luciferase-luciferin (LL) solution for ATP measurements. RBCs with FAM38A mutations 
of Piezo1 channels were obtained from patients with HX at the University of Rochester 
Medical Center under a material transfer agreement. 
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4.2.3 LL solution preparation 
PSS was prepared with 4.7 mM KCl, 2.0 mM CaCl2, 1.2 mM MgSO4, 140.5 mM 
NaCl, 21 mM Tris (hydroxymethyl)aminomethane, 11.1 mM dextrose, and 1 mg/ml BSA. 
The pH of the solution was adjusted to 7.4. D-luciferin and firefly luciferase were 
purchased from Sigma. LL solution was prepared by adding 1.7 mg D-luciferin and 100 μl 
firefly luciferase (1.0 mg/ml in PSS) into 5.0 ml PSS. PSS with different Ca2+ 
concentrations was prepared by dissolving a proper amount of CaCl2. The resulting 
solution was then titrated using 100 mM EDTA. Calcium concentration at the equivalence 
point was calculated using the Ca2+-EDTA binding constant Kd = 10
10.65 assuming 1:1 
binding of Ca2+: EDTA (Y4−). The fraction of EDTA (Y4−) is used as 3.8 × 10−4 at pH 7. 
Calcium-free buffer was obtained by preparing PSS without adding CaCl2 and including 
1.5 mM EDTA. A Ca2+-free firefly luciferase solution (1.0 mg/ml) was prepared by using 
calcium-free PSS. ATP-sodium salt solution was prepared in 100 μM stock solution using 
DI water, and then, the stock was diluted into PSS to generate specific concentrations for 
calibration experiments. Both LL and ATP-sodium salt solutions were prepared on the day 
of use. All chemicals, proteins, and enzymes were purchased from Sigma without 
additional purification. 
 
4.2.4 RBC deformability measurements 
To measure the deformability of RBCs, we diluted RBCs at ∼1.0% (v/v) in PSS 
and flowed the solution through another microfluidic constriction channel. The constriction 
channel dimensions used for cell deformability were 20 μm in width, 100 μm in length, 
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and 30 μm in height. The cells were injected at a flow rate of 3.0 μl/min, and high-speed 
videos are captured with a high-speed camera (Phantom M120; Vision Research). The 
videos were recorded at 1,900 frames per second with a resolution of 1,216 × 700. The 
videos were analyzed using Image J to determine the lengths of cells in pixels. 
 
4.2.5 ATP measurement 
We used a microfluidic channel with a constriction for shear-induced ATP 
measurement. The width of the channel before and after the constriction is 100 μm; the 
constriction is 20-μm wide (wc) and 800-μm long (lc). The height of the channel is 
uniformly 30 μm. Bioluminescent light was measured at different positions along the 
microfluidic channel by using a 63× oil objective on a microscope (Leica DMI 6000B; 
Leica). This objective has lower magnification than the one that we used in previous 
studies, resulting in a larger field of view. This large field of view has the consequence that 
sensitivity is increased slightly, because we are gathering light from a larger area, but 
temporal resolution is decreased, because cells remain in the field of view for longer 
periods of time. This lower temporal resolution results in an ATP release profile that is 
slightly different in appearance than that reported in previous studies [17]. The emitted 
light is passed to the photomultiplier detector, which is connected to the microscope by a 
C mount as a part of the separate photo detection system (RatioMaster; Photon 
International Technology). The time of release of ATP is then obtained by taking advantage 
of the space–time equivalence in time-invariant flows in microfluidic channels. All 
experiments were performed at room temperature (25 °C) and inside a dark room.  
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4.2.6 Ca2+ measurement 
The same microfluidic device used to measure ATP release was used to measure 
shear-induced Ca2+ influx. RBCs at 10% (v/v) were loaded with Fluo-4 by incubating the 
cells at 37 °C for 30 min in 5.0 μM Fluro-4 AM Dye (Life Technologies). Cells were then 
washed three times using a physiological salt solution and injected into the microfluidic 
device. Cells were excited at 488 nm with a monochromator light source (RatioMaster; 
Photon International Technology), and the emitted light intensity was measured with the 
photon detection system (RatioMaster; Photon International Technology) using a GFP 
filter. Images of cells stretched by fluid shear were taken with a digital charge-coupled 
device (CCD) (Hamamatsu ORCAR2; Hamamatsu). A 75-W Xenon Lamp (Leica) was 
used to excite the cells, and software exposure settings were kept the same throughout each 
experiment. 
 
4.3 Results and discussion 
4.3.1 Inhibition of Piezo1 impairs shear-induced ATP release and Ca2+ influx 
in human RBCs 
We have developed a microfluidic strategy to investigate the effects of Piezo1 on 
shear-induced ATP release and Ca2+ influx in human RBCs. The principle of the strategy 
is similar to our previously shown approach [17]. Briefly, a microfluidic channel with a 
constriction (lc = 800 μm; wc = 20 μm) is used to control the magnitude and duration of 
increased shear stress in flow, and the dynamics of shear-induced ATP release from human 
RBCs are studied with millisecond resolution. In particular, healthy human RBCs treated 
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with Piezo1 inhibitors (gadolinium (Gd3+) [58], ruthenium red [58], or the peptide 
Grammostola spatulata mechanotoxin 4 (GsMTx4) [82, 89]) or loaded with a Ca2+-
sensitive fluorescence dye (Fluo-4) were injected into the microfluidic channel at a 
constant flow rate (3 μl/min) (Figure 4-3A). The flow rate is chosen such that RBCs 
flowing inside the constriction channel experience a physiological level of shear stress 
comparable with that in arterioles [90, 91] (i.e., calculated average shear stress is ∼4 Pa in 
the constriction channel) (Table 4-1). In addition, the flow velocity in the channel does not 
change with time, and thus, the flow in the channel is steady. Because space and time are 
interchangeable for a steady flow, we are able to apply increased shear and measure the 
release of ATP and Ca2+ influx with millisecond resolution. The average flow velocity in 
the constriction channel (vc), for example, is ∼0.083 m s−1; the duration (tc) of increased 
shear is, thus, ∼9.6 ms (tc = lc/vc). To measure the amount of released ATP, we used the 
Luciferase-ATP bioluminescent reaction and detected photon emission rate by using a 
photon-counting photomultiplier tube (PMT). 
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Average concentration of released ATP was obtained based on an independently 
measured calibration curve. The magnitude of shear-induced Ca2+ influx (i.e., the 
fluorescence intensity of Fluo-4) was measured by using the PMT or a fluorescence 
camera. In addition, we used a high-speed camera to track the deformation of individual 
cells. 
Figure 4-3. Inhibition of Piezo1 impairs shear-induced ATP release from human RBCs. (A) 
Schematic of the microfluidic setup for measuring shear-induced ATP release from RBCs (not to 
scale). Note that x = 0 indicates the onset of increased shear. (B) Representative measurements of 
the photon emission rate resulting from the reaction between luciferase/luciferin and ATP for 
healthy control and GsMTx4-treated RBCs; t = 0 ms corresponds to the position of x = 0 in A. Note 
that GsMTx4 is a peptide that has been used to inhibit mechanically activated Piezo1 channels. The 
error bars are reported as the SDs of the mean (n = 11 and 4 for control and treated RBCs, 
respectively). (C) Average concentration of released ATP from control and Piezo1 inhibitor-treated 
RBCs. **: P < 0.01. (D) Superimposed series of time-lapse images showing the deformation of an 
individual RBC passing through a short constriction (lc = 100 μm; wc = 20 μm). (Scale bar: 20 μm.) 
(E) Normalized change of RBC length (measured in the flow direction) for cells passing through 
the short constriction shown in D (δL/L = Lstretched − Loriginal = Loriginal). Data were averaged from 
more than 30 cells for each sample. NS, not significant; RR, ruthenium red. 
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We showed that the amount of released ATP from GsMTx4-treated RBCs (10% 
v/v) was approximately twofold lower than that from untreated, healthy control RBCs 
(Figure 4-3B). In addition, control RBCs showed a peak of maximum ATP release between 
125 and 150 ms after the constriction, whereas treated RBCs had no such releasing pattern. 
Decreased ATP release was also observed when RBCs were treated with other Piezo1 
inhibitors (i.e., Gd3+ and ruthenium red), strongly suggesting that Piezo1 channels are 
involved in the regulation of shear-induced ATP release from RBCs (Figure 4-3C). To rule 
out the possibility that decreased ATP release might arise from the impaired deformability 
of RBCs on the treatment of Piezo1 inhibitors, we performed a cell deformability study by 
flowing control and Piezo1 inhibitor-treated RBCs through a short constriction channel (lc 
= 100 μm; wc = 20 μm) (Figure 4-3D). By measuring the change of RBC length using a 
high-speed camera, we found that there was no significant difference between control 
RBCs and treated cells (Figure 4-3E), indicating that treatment with Piezo1 inhibitors does 
not affect RBC deformability. 
Inhibition of Piezo1 channels reduces shear-induced Ca2+ influx in RBCs at both 
the single-cell and population levels. Images presented in Figure 4-4A show typical 
Table 4-1. Calculation of average shear stress in the constriction channe 
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responses of single RBCs to a flow-induced stretch in terms of Ca2+ influx. In the 
experiment, RBCs were loaded with Fluo-4 and immobilized at the bottom surface of the 
microfluidic channel, where an average wall shear stress was estimated as 3.4 Pa. Shear-
induced changes in fluorescence caused by Ca2+ influx were recorded using a fluorescence 
camera. The fluorescence intensity of control RBCs subjected to flow was significantly 
higher than that of RBCs treated with Piezo1 inhibitors (Figure 4-4B). 
At the population level, we flowed Fluo-4–loaded RBCs (10% v/v) through the 
microfluidic constriction channel (lc = 800 μm; wc = 20 μm) and examined the fluorescence 
intensity of RBCs before and after the constriction using a photon-counting PMT. Again, 
a significant increase of fluorescence intensity was observed only when control RBCs were 
flowing through the constriction channel (Figure 4-4C). In addition, the increase of Ca2+ 
influx occurs right after the constriction and continuously increases along the channel, 
which is unlike the pattern that we observed for shear-induced ATP release, in which the 
maximum release of ATP occurs a period after the constriction. 
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Figure 4-4. Inhibition of Piezo1 reduces shear-induced Ca2+ influx in human RBCs. (A) 
Fluorescence images of Fluo-4–loaded control and Piezo1 inhibitor-treated RBCs stretched by 
shear in a microfluidic device. Calculated average shear stress is ∼3.4 Pa. (Scale bar: 20 μm.) (B) 
Average fluorescence intensity of control and Piezo1 inhibitor-treated single RBCs. The error bars 
are reported as the SDs of the mean (n = 3). ***: P < 0.001. (C) Average fluorescence intensity of 
control and Piezo1 inhibitor-treated RBCs (10% v/v) flowing before and after the constriction 
channel. The error bars are reported as the SDs of the mean (n = 8 and 3 for normal RBCs and 
treated RBCs, respectively). NS, not significant; RR, ruthenium red. *: P < 0.05. 
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4.3.2 Shear-induced ATP release from human RBCs depends on Ca2+ influx 
and membrane-associated ATP pools 
To identify whether Ca2+ influx in RBCs is necessary for shear-induced ATP 
release, we compared the amount of released ATP from RBCs that were prepared in 
different concentrations of extracellular Ca2+. Tests on cells labeled with Fluo-4 revealed 
that the influx of calcium increased in proportion to the extracellular calcium concentration 
(Figure 4-5). In the absence of external Ca2+, ATP release remained at baseline (Figure 4-
6A). The average amount of released ATP remained almost unchanged (∼0.34 μM), even 
when the extracellular Ca2+ concentration increased from 0 to 0.5 mM (Figure 4-6B). When 
the extracellular Ca2+ concentration was above 0.5 mM, however, the average amount of 
released ATP increased significantly and in proportion to the extracellular Ca2+ 
concentration (Figure 4-6B). 
This observation indicates the existence of a threshold of extracellular Ca2+ 
concentration required for shear-induced ATP release. We further examined the correlation 
between shear-induced ATP release and Ca2+ influx by using RBCs from patients with HX, 
which is known to be associated with mutations of Piezo1 channels on RBCs [86-88]. Data 
in Figure 4-6C and D show that both the amount of released ATP and Ca2+ influx from HX 
RBCs decreased significantly, suggesting that mutant Piezo1 channels impair Ca2+ influx 
and consequently, reduce ATP release. 
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                 Lastly, we investigated the roles of membrane-associated ATP pools and ATP-
releasing channels in shear-induced ATP release from RBCs. Membrane-associated ATP 
pools in RBCs have been shown to be able to fuel RBC membrane cation pumps, including 
the Ca2+ pumps [92-94]. In particular, it has been suggested that membrane-associated ATP 
pools supply hypoxia-induced ATP release from RBCs [92]. 
Figure 4-5. Effect of extracellular Ca2+ concentration on shear-induced Ca2+ influx in RBCs. The 
error bars are reported as the SDs of the mean (n = 6, 4, 3, and 8 for 0, 0.5, 1, and 2 mM, 
respectively). 
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In our experiment, we measured the shear-induced ATP release from RBCs treated 
with ouabain, which is known to prevent bulk ATP from entering the ATP pools in RBC 
ghosts [93]. The results showed that ouabain-treated RBCs have a decreased amount of 
released ATP compared with control RBCs (Figure 4-7A), implying that limited access to 
Figure 4-6. Ca2+ influx regulates shear-induced ATP release from human RBCs. (A) Measurements 
of the photon emission rate caused by shear-induced ATP release in solutions with different 
concentrations of Ca2+. (B) Dependence of shear-induced ATP release on extracellular Ca2+ 
concentrations. (C) Ca2+ influx-induced increase of Fluo-4 intensity and (D) shear-induced ATP 
release from healthy control RBCs and RBCs from patients with xerocytosis. The error bars are 
reported as the SDs of the mean (n = 11 and 4 for control RBCs and RBCs from patients with 
xerocytosis, respectively). *: P < 0.05; ***: P < 0.001. 
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bulk ATP reduces shear-induced ATP release. Meanwhile, the release of ATP from 
ouabain-treated RBCs reached its maximum at ∼100 ms after the onset of increased shear, 
which is ∼50 ms earlier than that of control RBCs. In addition, we performed experiments 
with the pannexin-1 inhibitor carbenoxolone and the CFTR inhibitor glibenclamide to 
explore their roles in shear-induced ATP release. The results showed that the amount of 
released ATP decreases significantly (approximately twofold) in treated RBCs (Figure 4-
7B). 
Notably, the amount of released ATP from RBCs treated with both carbenoxolone 
and glibenclamide was not significantly different from RBCs that were treated with either 
carbenoxolone or glibenclamide alone. These findings indicate that carbenoxolone and 
glibenclamide do not distinguish between different potential ATP transport pathways. 
Furthermore, to determine the role of pannexin-1 relative to Piezo1 in terms of ATP 
release, we treated RBCs with both carbenoxolone and Piezo1 inhibitor GsMTx4 and 
measured ATP release. The results showed an additional reduced release of ATP (0.29 ± 
0.07 μM) (Figure 4-5B) compared with RBCs treated with either carbenoxolone (0.49 ± 
0.14 μM) (Figure 4-5B) or GsMTx4 (0.45 ± 0.05 μM) (Figure 4-3C) alone. 
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Figure 4-7. Effects of membrane-associated ATP pools and potential ATP-releasing channels on 
shear-induced ATP release from human RBCs. (A) Effect of ouabain treatment on shear-induced 
ATP release. Note that ouabain treatment is used to prevent bulk ATP from entering the membrane-
associated ATP pools in RBCs. (B) Effect of inhibition of CFTR and/or pannexin-1 and Piezo1 
channels on shear- induced ATP release. Carbenoxolone (Carben) and glibenclamide (Gliben) are 
used to inhibit pannexin-1 and CFTR, respectively. GsMTx4 is used to inhibit Piezo1 channels. 
The error bars are reported as the SDs of the mean (n = 4 for Carben and Carben/Glibentreated 
RBCs; n = 3 for Gliben-treated RBCs; and n = 4 for Carben/GsMTx4- treated RBCs). *: P < 0.05; 
**: P < 0.01; ***: P < 0.001. 
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4.3.3 Discussion 
The main finding presented here is that the mechanosensing cation channel Piezo1 
on RBCs regulates Ca2+ influx and participates in shear-induced ATP release. This finding 
is shown by measuring reduced ATP release and Ca2+ influx in RBCs that are treated with 
Piezo1 inhibitors. In addition, our data show that significant ATP release can be activated 
only when the extracellular Ca2+ concentration is above a threshold, suggesting a regulatory 
role of Ca2+ influx in ATP release. Thus, it is likely that shear-induced stretch of RBCs 
activates the mechanosensing cation channel Piezo1, which allows Ca2+ influx and 
consequently, induces ATP release from RBCs. A paper published after the initial 
submission of this report shows a role for Piezo1 in red cell volume regulation [95], but to 
the best of our knowledge, our study is the first to show a role of Piezo1 in the response of 
normal human RBCs to physiologically relevant fluid forces that could have relevance to 
the regulation of vascular tone. 
We previously identified two distinct timescales associated with the mechano-
transductive release of ATP from normal human RBCs [17] and showed that these were 
consistent with the physical processes described in a model of the process involving  CFTR 
and actin [79]. In addition, we investigated the links between single-RBC dynamics and 
ATP release and concluded, based on the effects of different inhibitors that CFTR and 
pannexin-1 respond differently to shear [16]. Carbenoxolone is a pannexin-specific blocker 
and has been used to block specifically pannexin activity in a wide range of cell lines, 
including RBCs [80, 96-99]. In studies that appeared subsequent to our prior report, 
however, it was shown that glibenclamide can attenuate pannexin-1 channel currents [100, 
101] and thus, is not specific to CFTR [102]. As a result, the decreased ATP release from 
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RBCs treated with both glibenclamide and carbenoxolone may reflect the reduced activity 
of pannexin-1 only. The role of CFTR in the process of ATP release is unclear [37, 103]. 
Early reports [76] implicated CFTR as a contributor to ATP release from RBCs based on 
inhibitor activity and different behaviors of red cells from cystic fibrosis patients. 
Subsequently, a direct role for CFTR in the release of ATP from RBCs was called into 
question for several reasons: first, the inability to detect CFTR in RBC membranes [104]; 
second, whether CFTR itself transports ATP remains controversial [105]; and third, the 
fact that inhibitors originally thought to act on CFTR preferentially also block ATP 
transport through pannexin-1 [100]. The most direct explanation for our results using 
carbenoxolone and glibenclamide is that ATP transport occurs primarily through pannexin-
1. The different ATP transport behavior in cystic fibrosis patients could be explained by a 
modulatory effect of CFTR on transport through pannexin-1. 
Our results here also show that ATP release correlates with Ca2+ influx and that the 
amount of released ATP and Ca2+ influx in HX RBCs is significantly lower than that in 
healthy control RBCs (Figure 4-6). HX is linked to mutations of Piezo1 channels on RBCs, 
and such mutations alter the kinetics of Piezo1 and lead to RBC dehydration and hemolytic 
anemia [87, 88]. The mutations result in two important differences in the kinetic behavior 
of the Piezo1 channels in HX cells: the rate of inactivation is slower (∼200 ms), and the 
latency to activation is longer [87, 88]. The slower rate of inactivation would be expected 
to extend the open time of the channels and lead to larger Ca2+ influx, contrary to 
experimental findings. Thus, the more important effect is most likely the longer latency 
period before activation, because this latency should lead to lower Ca2+ influx, consistent 
with experimental findings. In healthy RBCs, activation of Piezo1 is fast (i.e., within a few 
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milliseconds) [87]. In our experiment, the duration of increased shear (tc) is ∼9.6 ms, which 
is long enough to activate Piezo1 in healthy RBCs but much shorter than the latency for 
activation of mutant Piezo1 channels in HX RBCs. As a result, shear-induced Ca2+ influx 
in HX RBCs is significantly lower than that in healthy control RBCs in our experimental 
setup. 
We also consider the possible contributions of membraneassociated ATP pools in 
RBCs to the shear-induced ATP release. An estimate of the number of ATP molecules 
released per cell in our experiments indicates that the membrane pool of ATP is not large 
enough to account for all of the ATP released. The approximate number of ATP molecules 
released from single RBCs calculated from our data is ∼466,000 (Table 4-2).  
 
 
 
This value is about 20 times more than the pool ATP (e.g., ∼27,000 molecules of 
ATP for a typical RBC) [94]. Thus, it is unlikely that all of the released ATP comes from 
the ATP pools, unless there is a much more rapid refilling of the pool from bulk ATP than 
has been previously established. If it is true, as Chu et al. [92] suggest, that the released 
ATP comes from the membrane pool, then constant, facile access to bulk ATP (possibly 
because of membrane deformation) is presumably required to maintain the pool ATP for 
Table 4-2. Calculation of ATP release from single RBCs.  
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release. This scenario is consistent with our observations of the inhibitory effects of 
ouabain that we have observed. Experiments on RBC ghosts have led to the conclusion 
that ouabain acts to prevent replenishment of the membrane pools from bulk ATP. This 
limited access of membrane-associated ATP pools to the bulk ATP because of ouabain 
treatment would result in a reduced amount of releasable ATP in the pools and 
consequently, a decreased ATP release, which we have observed. It should be noted, 
however, that ATP compartmentation in human RBCs was discovered in RBC ghosts, and 
direct evidence of the presence of ATP pools in intact RBCs remains elusive, although 
indirect arguments in favor of the presence of pools in intact cells have been made [93, 
106]. 
Our results, however, raise the question of how Ca2+ influx in RBCs relates to ATP 
release. The dependence of ATP release on intracellular Ca2+ has been shown in various 
cell lines, including urothelial and endothelial cells [107, 108]. Indeed, functional roles of 
Piezo1 in stretch-evoked Ca2+ influx and ATP release in urothelial cell cultures have been 
shown recently [107]. In these cell types, however, a Ca2+-regulated vesicular exocytosis 
is commonly involved in the process of ATP release. RBCs are lacking organelles, such as 
the Golgi complex, to form vesicles, and consequently, the Ca2+-regulated vesicular 
exocytosis is not applicable to the observed relation between Ca2+ flux and ATP release 
from RBCs. However, it has been shown that locally increased Ca2+ levels near the RBC 
plasma membrane reduce the interactions between 4.1R and the spectrin-actin network 
[109] and increase the depolymerization of actin filaments [110]. Given that CFTR can be 
activated by membrane-associated actin molecules and induces ATP release [76, 79], it is 
possible that Ca2+ participates in the process of ATP release by modulating the interactions 
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between actin and CFTR. Furthermore, because pannexin-1 channels can be activated by 
cytoplasmic Ca2+ [111], it is also possible that shear-induced Ca2+ influx activates 
pannexin-1 directly and triggers ATP release. 
However, Piezo1 inhibitors do not block completely Ca2+ influx (Figure 4-4B), and 
thus, a basal ATP release is still observed (Figure 4-3C). This basal ATP release can be 
further reduced when both Piezo1 and ATP-releasing channel pannexin-1 are inhibited 
(Figure 4-7B, carbenoxolone and GsMTx4 treatment). In this case, the amount of released 
ATP (0.29 ± 0.07 μM) (Figure 4-5B) is comparable with that of ATP released in 0 mM 
extracellular Ca2+ solution (0.34 ± 0.02 μM) (Figure 5-6B), emphasizing the regulatory 
role of Ca2+ influx in ATP release. The fraction of released ATP inhibited by 
carbenoxolone (0.49 ± 0.14 μM) (Figure 5-7B), however, is approximately the same as that 
inhibited by Piezo1 inhibitor GsMTx4 (0.45 ± 0.05 μM) (Figure 4-3C). 
Shear-induced Ca2+ influx can activate plasma membrane Ca2+ ATPase (PMCA) 
[112-114] that pumps extra Ca2+ out of the cell rapidly. As a result, intracellular Ca2+ 
decreases quickly, which may down-regulate the ATP release. Indeed, considering the 
kinetics of PMCA activity and the timeframe of ATP release, this mechanism seems 
feasible. The turnover rate of PMCA is 50–300 per second [115, 116], the number of pump 
units per cell is 400–700 [116], and the increased intracellular Ca2+ levels in RBCs caused 
by the mechanical deformation are 12–24 nM [114]. Combining these numbers, we 
estimate a timescale for PMCA to remove the extra Ca2+ of 30–100 ms, which is 
comparable with the duration of ATP release (∼100 ms). 
Therefore, it seems likely that the parallel activities of PMCA and ATP release 
compete in Ca2+ use inside the cell and that the dynamic concentration of intracellular Ca2+ 
84 
 
determines the patterns of ATP release. When a slight increase of intracellular Ca2+ occurs 
because of shear-induced Ca2+ influx, for example, PMCA pumps the extra Ca2+ out of the 
cell, rapidly leaving a negligible amount of Ca2+ to trigger ATP release. When intracellular 
Ca2+ increases significantly, however, it will take a period for the PMCA to pump the extra 
Ca2+ out of the cell, and consequently, there will be a sufficient amount of intracellular 
Ca2+ to trigger ATP release. After extra intracellular Ca2+ ions are pumped out completely, 
ATP release stops. This process explains the existence of a threshold of extracellular Ca2+ 
concentration that triggers ATP release and the transient ATP release patterns that we 
observed in this study and previous studies. Collectively, we propose a model to account 
for the observed mechanotransductive release of ATP from RBCs (Figure 4-8). 
It is important to note that our data indicate that Ca2+ influx is important for 
mechanically induced ATP release, but whether this observation results from modification 
of cytoskeletal stability or whether the release might be modulated by either PMCA activity 
or Ca2+ acting directly on ATP release channels remains to be determined. In addition, our 
data show that neither inhibitors nor mutation can block ATP release or Ca2+ entry 
completely. Instead, the decrease in ATP release and Ca2+ entry brought about by inhibitors 
or mutation is about one-half of the normal amount. Furthermore, basal ATP release can 
still occur when extracellular Ca2+ is 0 mM (Figure 4-6B) or both Piezo1 and pannexin-1 
channels are inhibited (Figure 4-7B). 
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These results, thus, suggest that (i) Ca2+ influx is necessary only when a significant 
amount of ATP release is required and (ii) pathways other than Piezo1-regulated Ca2+ 
influx also participate in shear-induced Ca2+ entry and ATP release. 
 
4.4 Conclusion 
In summary, we illustrate for the first time, regulatory role of Piezo1 in shear-
induced ATP release from human RBCs and provide evidence for a Ca2+-triggered ATP 
Figure 4-8. Schematic of the proposed mechanotransductive release of ATP from RBCs. (A) Shear-
induced stretch of RBCs activates Piezo1 channels and induces an increased Ca2+ influx, which (B) 
activates Ca2+ pumps to remove extra Ca2+ rapidly. (C) Meanwhile, increased Ca2+ influx activates 
pannexin-1 channels (Px1) directly and triggers ATP release from the membrane-associated ATP 
pools. (D) It is also possible, although controversial, that increased Ca2+ influx depolymerizes actin 
filaments (brown spheres), which activates CFTR and induces the release of ATP. Regardless of 
the precise mechanism, our results show clearly that a critical concentration of intracellular Ca2+ 
caused by shear-induced Ca2+ influx is required for the mechanotransductive release of ATP 
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release model. These results represent a substantial step forward in understanding the 
mechanotransductive release of ATP from RBCs, which will be critical to the development 
of improved therapeutic strategies for red cell dysfunction and vascular disease. After such 
strategies become available, for example, in diseases that are associated with impaired ATP 
release from RBCs, pharmacologic regulation of the calcium influx in RBCs could be used 
to achieve enhanced ATP release. Conversely, when less ATP release is needed (for 
example, to store RBCs or in the case of handling blood using mechanical devices), the 
calcium influx could be decreased. Decreasing activity of Piezo1 is likely to be sufficient 
for this purpose. Thus, important advances in the therapy of diseases and complications 
that are associated with the release of ATP from RBCs are expected. In addition, because 
of the high spatiotemporal resolution of the developed microfluidic approach, we anticipate 
that the experimental procedure developed here will be useful for elucidating the dynamics 
of Piezo1 channels at the whole-cell level, which has been known to be critical and much 
needed for extrapolation of patch recordings results to functionality [117]. 
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5. CONCLUSION 
RBC is the major cell type in the body, and they are responsible for oxygen 
exchange in the body. There is no nucleus in RBCs and due to the structure and its surface-
to-volume ratio, they are deformable and play an important role in microcirculation. In our 
work, we illustrated that RBCs can sense oxygen level and modify their membrane in blood 
flow. It was found that RBC membrane became more stretchable under hypoxia, which 
made it smoother for them to pass through the capillaries. To better understand the 
mechanism of RBC membrane modification under hypoxia, we studied the interactions 
between protein membrane, band 3, ankyrin, and deoxyHb. It was shown in both ex vivo 
and in vivo experiments that during deoxygenation, deoxyHb-band 3 interaction increased 
while band 3-ankyrin interaction decreases. As a result, the association between cell 
membrane and cytoskeleton was compromised, which lead to a more deformable 
membrane and eventually facilitated the blood flow in capillaries. Additionally, we studied 
the RBC function in flow condition where they experienced shear stress. It was known that 
the mechanosensitive channel, Piezo1, on cell membrane was activated which triggered 
shear-induced Ca2+ influx. From our work, we concluded that shear-induced Ca2+ influx 
through Piezo1 channel was critical to RBC ATP release. Summarily, our work built the 
connection of the dynamic roles of RBCs in different conditions. With the more in depth 
understanding, we could have more knowledge about different disease models that are 
linked with blood flow dysfunction, such as Alzheimer’s disease, sepsis, sick cell disease 
and so on. Through our work, we may have potential development of therapeutic strategies 
for the diseases.  
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6. APPENDIX 
❖ MICROFLUIDIC ASSAY OF THE DEFORMABILITY OF 
PRIMITIVE ERYTHROBLASTS 
Primitive erythroblasts (precursors of RBCs) enter vascular circulation during the 
embryonic period and mature while circulating, hereby experiencing significant 
hemodynamic shear stress. Shear-induced deformation of primitive erythroblasts, 
however, is poorly studied. In this work, we examined the deformability of primitive 
erythroblasts at physiologically relevant flow conditions in microfluidic channels and 
identified the regulatory roles of the maturation stage of these erythroblasts and 
cytoskeletal protein 4.1 R on shear-induced cell deformation. The results showed that the 
maturation stage affected the deformability of primitive erythroblasts significantly, that at 
later maturational stages exhibit an improved deformability due to the matured cytoskeletal 
structure in the cell membrane.  
 
 
 
 
 
Reproduced from [118], with the permission of AIP Publishing  
89 
 
6.1 Introduction 
Primitive erythroblasts are precursors of erythrocytes and essential to the 
regeneration of erythrocytes and fetal development. They carry both embryonic and adult 
hemoglobin while “definitive” cells only accumulate adult hemoglobin [3, 5, 6, 10]. 
Similar to the process in mouse, nucleated primitive erythroblasts join the yolk-sac 
circulation from the fourth to fifth week of gestation [5] in humans. As shown in Figure 6-
1, definitive cells rapidly dominate the cell population at around E14.5 and E15.5. Also, it 
is confirmed that primitive red cells have significant bigger size than definitive cells. 
Primitive erythroblasts can be further identified in the embryo after 6 weeks [3]. Starting 
from the eighth week, definitive cells from the liver are observed while primitive 
erythroblasts are still the majority [3]. Due to the similar maturation process of primitive 
erythroblasts in humans and mouse, many studies of primitive erythroblasts are conducted 
in mouse embryos. 
            In mouse embryo, primitive erythroblasts mature as a semi-synchronous cohort 
over the next several days as they circulate in the bloodstream. Primitive erythroblasts 
transit from pro-erythroblasts at E9.5 to orthochromatic erythroblasts at E12.5 and then 
enucleate over the subsequent 4 days of gestation [5, 7] to produce mature erythrocytes. 
The circulation of primitive erythroblasts also contributes to the formation and remodeling 
of blood vessels in the yolk sac. Without the presence of such circulation, for example, 
regular development of the embryo such as vessel remodeling and maturation is impaired 
[119-121]. 
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Primitive erythroblasts experience shear stresses in the fetal bloodstream and have 
to move throughout the embryonic microvasculature that has a diameter from 4 µm to 60 
µm [11]. Because the size of primitive erythroblasts with maturation stages from E8.5 to 
E12.5 varies from 17 µm to 13 µm [122], flexibility and elasticity that allow the primitive 
erythroid cells to move through the embryonic microvasculature are crucially important. 
Although the structure and composition of the cytoskeletal network in adult erythrocytes, 
as well as their deformability, are well established, the deformability of maturing 
Figure 6-1. Changes in cellular composition of blood from E11.5 to E14.5 of mouse gestation. In 
A, C, E and G, gray area shows the cell size distribution of circulating blood cells, while black area 
indicates a sample of adult murine red cells. The y-axis indicates the relative cell number and x-
axis represents cell volume. B, D, F and H represent the pictures of cells with nuclei and after 
enucleation. 
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erythroblast precursors is less understood. One of the possible reasons is that protein 
composition in the cytoskeleton of primitive erythroblasts changes with the maturation 
stage. Decreases in surface area (about a 35% loss), volume (50% loss), and sphericity (6% 
loss) along maturation have been observed and can be attributed to the membrane and 
cytoskeleton protein remodeling (Figure 6-2) [123]. Remodeling also leads to a reduced 
stiffness of the cell membrane [123]. In addition, as primitive erythroblasts mature, shear 
stress activates intracellular kinases to remodel the membrane and cytoskeletal 
compositions [120]. Without the correct protein components that make up the cytoskeleton 
network such as actin, spectrin, and protein 4.1R [124], erythroid cells will have a less 
deformable cytoskeleton network that could potentially lead to hemolytic anemia [125]. 
While the structural remodeling of the membrane and cytoskeleton of primitive 
erythroblasts has been investigated, flow-induced deformation of primitive erythroblasts at 
different maturation stages is less studied. In addition, although defects of protein 4.1 R 
are tightly linked to hereditary elliptocytosis [126], characterized by morphologically 
abnormal and mechanically unstable erythrocytes [127-133], the regulatory role of protein 
4.1 R in erythroblast deformation remains unknown. 
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Although studies of deformability-induced red cell migration have been conducted 
in small capillaries under a bulk suspension [134, 135], we here developed microfluidic 
approaches to study the deformability of single primitive erythroblasts under 
physiologically relevant flow conditions. We determined the effect of maturation stage on 
the deformability of primitive erythroblasts and unveiled the regulatory roles of protein 4.1 
R in cell deformation. Lastly, we investigated the deformability of primitive erythroblasts 
when squeezing through a narrow constriction channel mimicking the size of the capillary. 
 
Figure 6-2. Changes in cell dimensions within gestational age. Between E12.5 and E14.5, the 
change in cell surface and volume is not noticeable. Decreases in surface area, volume, and 
sphericity can be observed after E14.5.  
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6.2 Experimental methods 
6.2.1 Mice and collection of embryonic peripheral blood 
All animal experiments were approved by the University of Rochester Committee 
on Animal Resources (UCAR). Epb4.1+/+ and Epb4.1-/- mice [126] were provided by Dr. 
John Conboy (Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, 
CA). 
Outbred ICR (Taconic Biosciences, Germantown, NY) and Epb4.1+/- mice were 
mated overnight, and vaginal plugs were checked the following morning (embryonic day 
0.3; E0.3). At defined gestational ages, mice were sacrificed by CO2 narcosis and the 
embryos were dissected in PB2 [136, 137] containing 12.5 µg/ml of heparin. E10.5 and 
E12.5 embryos were bled in PB2 and the embryonic peripheral blood was collected from 
the bottom of the dishes. Total cell numbers and viability were determined by trypan blue 
staining (Sigma-Aldrich). Embryos from Epb4.1+/- mouse mating were genotyped using 
the AccuStartTM II Mouse Genotyping Kit (Quanta Biosciences) with primer pairs as 
follows: neo (neo-f, 5’-GATGGATTGCACGCAGGT-3’; neo-r, 5’-
GGCAGGAGCAAGGTGAGA-3’; 318 bp) [138]; Epb 4.1 exon 4 (Epb4.1E4-f, 5’-
GCTCAGGAAGAACACAGAGAGG-3’; Epb4.1E4-r, 5’-
CATTCGTAGACCGTGTCATCC-3’; 197 bp) [138]. 
 
6.2.2 Microfluidic fabrication and experimental setup 
PDMS chips were fabricated using standard soft photolithography techniques. The 
channel inside of the PDMS chip has a uniform length of 100 µm (lc = 100 µm) and a width 
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of 20 µm (wc = 20 µm) at a constriction section, and a width of 100 µm for the rest of the 
channel. The height of the channel is 30 µm (h = 30 µm) everywhere. To test the 
deformability in a narrow microfluidic channel, we fabricated a microfluidic channel with 
lc = 170 µm, wc = 5 µm, and h = 7 µm, which mimics the size of capillaries [11]. Using a 
1mL syringe and needle (Med Lab Supply), the suspension of primitive erythroblasts 
collected from mouse embryos (2 v/v % in PBS) was transferred to polyethylene tubing 
[Scientific Commodities Inc, 0.015” (0.38 mm) I.D.× 0.043” (1.09 mm) O.D.], which was 
then inserted into the microchannel after removing air bubbles. The primitive cells in the 
microfluidic channel were visualized using a Leica microscope (Leica Microsystems, DMI 
6000) with a 63× oil-immersion objective. A syringe pump (KD Scientific) was introduced 
to maintain the flow rate of 0.75 µl/min, 1.5 µl/min, or 3 µl/min. 
Videos of the primitive cells flowing through the microchannel were recorded using 
a high-speed camera (Sample rate: 1900 pps, Phantom) coupled to the Leica microscope. 
Phantom Camera Control software (PCC) from Vision Research Inc. was used to analyze 
the elongation of the cell Dl/Dw, where Dl and Dw are the length and width of the cell, 
respectively. The position of the entrance of the constriction channel is defined as t = 0 ms. 
The time frame of cells on corresponding positions was calculated based on the time 
interval between each frame (526 µs). 
             
6.2.3 Preparation of primitive erythroid cell lysates 
E12.5 primitive erythroblasts were washed 3 times with phosphate-buffered saline 
(PBS, 300 mOsm/kg), and then resuspended in RIPA buffer [139, 140] (50mM Tris 
[tris(hydroxymethyl)aminomethane], 150mM NaCl, 1% Nonidet P-40 or 1% Igepal CA-
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630, Sigma-Aldrich; 0.1% SDS, 0.5% sodium deoxycholate, 1mM EDTA 
[ethylenediaminetetraacetic acid], 1mM DTT [Dithiothreitol], pH 8.0) in the presence of 
complete protease inhibitor cocktails (Roche), 25 µg/ml PMSF, and 1mM Na3VO4, and 
incubated on ice for 30 min. Nuclei and debris were separated by centrifugation at 500 g 
for 10 min at 4 ˚C. Samples were stored at -80 ˚C until analysis. 
 
6.2.4 Immunoblotting analysis 
Erythroid cell lysates from 5 × 1031 cells were separated by 4%–20% SDS-PAGE 
(Bio-Rad) and transferred to PVDF membranes (EMD Millipore). The membranes were 
blotted with antibody in 5% (w/v) nonfat dry milk (Bio-Rad) in TBST (50mM Tris, 150mM 
NaCl; 0.1% [v/v] Tween-20) and washed in TBST. The signal was detected using the 
Pierce ECL Plus Western Blotting Substrate (Thermo Scientific) and developed on a 
BioMax XAR film (Carestream). Anti-protein 4.1 R antibody (NY Blood Center, NY) 
[123], anti-β-actin antibody (Sigma-Aldrich), and HRP-conjugated secondary antibodies 
(Bio-Rad) were used in immunoblotting analysis. 
6.2.5 Cell Stain 
E10.5 erythroblasts were suspended in 10% Normal Rat Serum (NRS; Invitrogen) 
and block on ice for 15 min. To stain the cell membrane, 1:100 Alexa Fluor 488-Ter119 
(BioLegend) was added on ice for 20 min, followed by one-time wash using PB2. Cells 
were then resuspended in PB2 and stained on ice using DRAQ5 (eBioscience) for another 
5 minutes, after which the cells were ready for imaging [141]. 
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6.3 Results and discussion 
We investigated the deformability of primitive erythroblasts by flowing them 
through a constriction channel (wc = 20 µm, h = 30 µm, and lc = 100 µm) embedded in a 
microfluidic device (Figure 6-3A). Because the estimated thoracic aortic shear stress in the 
embryonic circulation of mouse embryo is about 3.8 Pa [142], the volumetric flow rates 
used in the current study were 0.75 µl/min, 1.5 µl/min, and 3 µl/min, which provided 
approximately shear stresses of 1.05 Pa, 2.1 Pa, and 4.2 Pa, respectively. In Figure 6-3B, t 
= 0 ms was assigned to the time at which the primitive erythroblast entered the constriction 
channel. An increase of Dl/Dw was observed before t = 526 µs, and then Dl/Dw decreased, 
indicating that the cell elongated upon entering the channel and recovered while exiting the 
constriction channel (Figure 6-3B). The results were consistent with the deformation of 
mature red blood cells flowing through constriction channels [43] and suggested that 
primitive erythroblasts were deformable at E12.5. 
We then studied the effect of flow rate (or shear stress) on the deformation of 
primitive erythroblasts at two different maturation stages, i.e., E10.5 and E12.5. The results 
showed that E12.5 cells did not deform significantly when the flow rate was increased from 
0.75 µl/min to 1.5 µl/min. The maximum elongation index, however, increased 
significantly (p < 0.0001) when the flow rate was increased to 3 µl/min. 
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Because shear stress at the flow rate of 3 µl/min is approximately 4.2 Pa, close to 
the estimated shear stress in the embryonic circulation of mouse embryo, the increased 
elongation index at the flow rate of 3 µl/min demonstrates that E12.5 cells will deform 
significantly in physiologically relevant flow conditions. As to E10.5 cells (Figure 6-4B), 
the elongation index did not show a significant difference when the flow rate increased 
from 0.75 µl/min to 1.5 µl/min. The elongation index started to increase when the flow rate 
Figure 6-3. Experimental setup of the microfluidic assay of the deformability of primitive 
erythroblasts. (A) Schematic of the microfluidic approach to examine the deformation of primitive 
erythroblasts. The length (lc) and width (wc) of the constriction channel are 100 µm and 20 µm, 
respectively. The height of the channel is 30 µm. The arrow indicates the direction of flow. (B) 
Change of the elongation index (Dl/Dw) of primitive erythroblasts at E12.5 passing through the 
constriction channel. Flow rate = 1.5 µl/min. Time = 0 ms corresponds to the position of the 
entrance of the constriction channel. The inset is an image of a primitive erythroblast at E12.5 and 
the definition of Dl and Dw (n = 39). 
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was 3 µl/min. To compare the deformability of E12.5 and E10.5 under the same flow rate, 
we examined the change of the maximum elongation index of both cells. The results 
showed that E12.5 cells always had a significantly higher elongation index than that of 
E10.5 cells (p < 0.0001) (Figure 6-4C), indicating that cells at E12.5 were more stretchable 
than the ones at E10.5. The lack of significant increase of the elongation index with 
increased shear stress indicated the finite stretchability of E10.5 cells, which might arise 
from the immature cytoskeletal network or the lack of excess of membrane materials for 
the given cytoplasmic volume that consequently constrains the deformability of 
erythroblast cells. 
We have shown recently an increased expression of 4.1 R transcripts as erythroblast 
cells transit from E10.5 to E12.5 and that an erythroid-specific isoform switch occurs 
between E10.5 and E11.5 [141]. Because 4.1 R can form a ternary complex with actin and 
spectrin and plays important roles in maintaining the integration of the cytoskeletal 
network of mature erythrocytes [143], it is likely that protein 4.1R in the cytoskeletal 
composition between E10.5 and E12.5 is, in part, responsible for the observed phenomena 
in erythroblast cells. 
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            To confirm the role of 4.1R in erythroblast deformability, we tested the shear-
induced deformation of primitive erythroblasts from Epb4.1 knockout (KO) mice. As 
Figure 6-4. Effect of flow rates on the change of elongation index of primitive erythroblasts at (A) 
E12.5 (n = 173) and (B) E10.5 (n = 68). (C) Effect of flow rates on the change of maximum 
elongation index (Dl/Dw) of primitive erythroblasts when passing through the constriction channel. 
The Student’s t-test showed significant difference between E10.5 and E12.5 cells when applying 
the same flow rate (****: p < 0.0001). 
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shown in the Western Blot analysis depicted in Figure 6-5A, control samples with 
Epb4.1+/+ showed the presence of protein 4.1 R, wherease primitive erythroblasts from 
Epb4.1 KO mice lacked the protein 4.1R. Actin was used as the control to demonstrate that 
actin was well expressed for both non-KO and KO cells and was detectable. When the 
deformatibilty of primitive erythroblasts at E12.5 from Epb4.1 KO mice was studied in the 
same flow conditions as described above, the elongation index decreased compared to the 
wild type (Figures 6-3B and 6-4A). With the increase of flow rates, the deformation of 
protein 4.1 KO cells did not change significantly. The E12.5 protein 4.1 KO primitive 
erythroblasts, in fact, showed similar patterns with E10.5 primitive erythroblasts under the 
same flow rates (Figure 6-4B), suggesting that protein 4.1 KO E12.5 cells have the similar 
deformability as wild type E10.5 primitive erythroblasts. However, when the flow rate 
increased to 3 µl/min, there was no obvious change in protein 4.1 KO E12.5 cells, while 
the E10.5 cells can be stretched more under higher shear stress. Because protein 4.1R is 
critical to the formation of nodal junctions (with actin and spectrin) of the membrane-
skeletal network [143] and the maximum local extension of the cell membrane depends on 
the difference between the average separation of the junctions and the contour length of 
the spectrin tetramers [144], the lack of 4.1R in the membrane of erythroblasts likely 
impairs the connections between spectrin and/or the spectrin dimer-tetramer equilibrium. 
It attributes to the failure of forming the functional membrane skeleton network [141]. A 
recent study shows that due to the absence of 4.1 R, E12.5 primitive cells cannot transform 
from spherical to partially concave in shape, leading to a relatively small surface-to-volume 
ratio [141], which consequently results in decreased cell deformability [145, 146]. 
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Last, to examine the erythroblast deformability in capillaries where cells have to 
squeeze through the narrow capillary, we flew erythroblasts through a microfluidic device 
with a much narrower constriction channel that has dimensions of wc = 5 µm, lc = 170 µm, 
and h = 7 µm. In this case, both the membrane and nucleus of the cells are expected to be 
deformed (Figure 6-6). The results showed that, when individual primitive erythroblasts 
flew through the constriction channel at a constant flow rate (0.5 µl/min), cells at E12.5 
could squeeze through the constriction without compromising the integrity of the cell and 
elongate to almost twice their original length. After exiting the constriction channel, the 
E12.5 primitive erythroblasts were able to recover their original morphology with a slightly 
plastic deformation (Figure 6-6A).  
Figure 6-5. Effect of 4.1R on the deformability of primitive erythroblasts. (A) Expressions of 
cytoskeletal proteins (4.1R and actin) in knockout (KO) and non-KO E12.5 cells. (B) Effect of flow 
rates on the elongation index of primitive erythroblasts at E12.5 from Epb4.1 KO mice (n = 135). 
102 
 
 
 
In contrast, when primitive erythroblasts at E10.5 were pushed through the 
constriction channel, the cells lysed before exiting (Figure 6-6B). The results showed that 
in the conditions of high shear stress and signficant deformation, E12.5 cells were more 
deformable than those of E10.5. It should be noted, however, that the results did not suggest 
that the nucleus of E12.5 was more deformable than that of E10.5. Although most of the 
nuclei of E10.5 primitive erythroblasts are lysed while being squeezed inside the 
Figure 6-6. Deformation of primitive erythroblasts flowing through a narrow microfluidic channel 
(lc = 170 µm, wc = 5 µm, and hc = 7 µm). The white arrows indicate the flow direction. (A) 
Superimposed series of time-lapse images showing the deformation of an individual primitive 
erythroblast at E12.5 passing through a narrow constriction. (B) A sequence of images of primitive 
erythroblasts at E10.5 flowing through the narrow constriction. Note that the black arrow (iii) 
indicates the place where cell starts to lyse, and the white arrow indicates the direction of flow. 
(Scale bar 10 µm).  
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constriction channel, (Figure 6-7A and B), there are still some nuclei that are intact after 
going through the constriction (Figure 6-7C). 
In addition, it was known that at the late stage of maturation (E12.5-E16.5), 
interactions between cytoplasmic proteins and the nucleus in primitive erythroblasts are 
attenuated or lost in preparation for enucleation [1, 124, 147, 148]. It is thus possible that 
the shear force experienced by the membrane of E12.5 cells was not transmitted to the 
nucleus when passing through the narrow constriction. More importantly, the diameter of 
primitive erythroblasts decreased from ~15 µm to 13 µm when cells transited from E10.5 
to E12.5 during embryonic development [122]. At the same time, the size of nuclei was 
reduced from ~10 µm for cells at E10.5 to ~5 µm for cells at E12.5 due to nuclear 
condensation [122]. With the comparable size of the channel with the size of the nucleus 
and the deformable membrane of E12.5 primitive cells, the shear force experienced by the 
E12.5 cells may not be transmitted to the nucleus. Thus, the observed lysis of E10.5 
primitive erythroblasts may be due to the decreased membrane deformability and the large 
size and tethering of the nucleus. 
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6.4 Conclusion 
In summary, by mimicking the physiologically relevant flow conditions using 
microfluidics, we observed that E12.5 erythroblasts were more deformable than E10.5 
erythroblasts under different shear conditions and could recover to their original shape after 
shear-induced deformation. Thus, the deformability of primitive erythroblasts changes 
during maturation and primitive erythroblasts at late maturational stages are more 
Figure 6-7. Microscopic images showing E10.5 cells before flow (A), inside constriction channel 
(B) and in the downstream channel after going through the constriction (C). Cell membrane was 
stained by Ter119 (green) while the nuclei were stained using DRAQ5 (blue). After being squeezed 
in the constriction channel, cell membrane and a portion of nuclei were lysed. Note that some of 
the nuclei remained intact after experiencing such shear stress. (Scale bar: 10 μm) 
 
Figure 2-8. Ex vivo experiments of velocity measurement under hypoxia. (A) A diagram of the 
experimental setup for ex vivo analysis of the effect of PO2 on RBC flow velocity. Human RBCs 
were added to the bath containing PBS and forced to flow through a microfluidic device containing 
a narrow channel by applying a constant pressure (1.6 psi). The microfluidic device was submerged 
in an O2 sink (chamber containing H2O with 0.0, 0.01, 0.1, or 1.0 M sodium sulfite). PO2 in the 
microfluidic channel was successively lowered by increasing the concentration of sulfite in the O2 
sink (0.0–1.0 M). RBC motion was captured by a high-speed camera. (B) Left: colorimetrically 
quantify PO2 in the capillary channel. The change in fluorescence intensity of the O2 indicator dye 
solution flowing through th  microfluidic device was measur d during exp sure to 0.0, 0.01, .1,
1.0, 1.5, and 2.0 M sodium sulfite solution and converted to PO2. Right: images comparing RBC 
flow within an O2 sink containing 0 or 1 M sulfite. Images of flowing RBCs captured by the high-
speed camera at sequential time points are superimposed.Figure 6-9. Microscopic images showing 
E10.5 cells before flow (A), inside constriction channel (B) and in the downstream channel after 
going through the constriction (C). Cell membrane was stained by Ter119 (green) while the nuclei 
were stained using DRAQ5 (blue). After being squeezed in the constriction channel, cell membrane 
and a portion of nuclei were lysed. Note that some of the nuclei remained intact after experiencing 
such shear stress. (Scale bar: 10 μm) 
 
Figure 2-10. Ex vivo experiments of velocity measurement under hypoxia. (A) A diagram of the 
experimental setup for ex vivo analysis of the effect of PO2 on RBC flow velocity. Human RBCs 
were added to the bath containing PBS and forced to flow through a microfluidic device containing 
a narrow channel by applying a constant pressure (1.6 psi). The microfluidic device was submerged 
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deformable. This is likely due to the integration of a critical cytoskeletal protein such as 
protein 4.1 R in the membrane at the late maturational stage of primitive erythroblasts. In 
addition, we demonstrated that the deformatibility at E12.5 was higher than that at E10.5 
when transpassing narrow constrictions with a similar size of capillaries, further supporting 
the notion that the maturation of primitive erythroblasts plays a key role in cell 
deformation. The findings here provide new insights into the deformation of primitive 
erythroblasts under flow conditions and are important for understanding the evolution of 
microcirculation in fetus and how it facilitates the oxygen and nutrition transportation 
providing the necessary physiological environment. 
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